KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
Kol Lebenslauf für Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Einflussstatistik
Bericht ausführen
| Concept | World rank |
|---|---|
| akc administration | #1 |
| conjunctivitis concomitantly | #1 |
| patients allergic conjunctivitis | #1 |
| tranilast production | #1 |
| severity objective signs | #1 |
| atopic keratoconjunctivitis | #1 |
| capilia adeno | #1 |
| 0001 allerwatch | #1 |
| tacrolimus eye | #1 |
| bromfenac sodium treatment | #1 |
| akc | #1 |
| bak epithelium disorders | #1 |
| efficacy fml | #1 |
| levocabastine artificial | #1 |
| 01 ophthalmic solution | #1 |
| release inhibitor purpose | #1 |
| akc allergic | #1 |
| akc compared | #1 |
| immunocytochemical study rtpcr | #1 |
| conclusions objective assessments | #1 |
| primary human conjunctival | #1 |
| tacrolimus tears | #1 |
| rsv conjunctival | #1 |
| antagonists child conjunctivitis | #1 |
| atopic keratoconjunctivitis akc | #1 |
| suspension treating | #1 |
| sodium allergic | #1 |
| conjunctival fibroblasts | #1 |
| bromobenzenes conjunctivitis | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| eye fml | #1 |
| allerwatch higher | #1 |
| eyebon | #1 |
| tranilast dexamethasone | #1 |
| itchy sensation | #1 |
| eyewash solutions bak | #1 |
| incubated interleukin | #1 |
| allergens levocabastine | #1 |
| hundredandseventy eyes | #1 |
| cox2 conjunctival | #1 |
| artificial tears positive | #1 |
| eye surface years | #1 |
| objective findings conclusions | #1 |
| conjunctivitis aims | #1 |
| conjunctival cedar | #1 |
| ige allerwatch | #1 |
| rate allerwatch | #1 |
| fumarate dexamethasone | #1 |
| akc methods | #1 |
| ketotifen fumarate dexamethasone | #1 |
| allergic enzyme | #1 |
| satisfaction suspensions | #1 |
| 12 patients akc | #1 |
| cases severe conjunctivitis | #1 |
| vkc cases | #1 |
| pcr eotaxin1 | #1 |
| bromfenac sodium bf | #1 |
| allergic conjunctivitis efficacy | #1 |
| epithelial pge2 | #1 |
| tears allergic patients | #1 |
| conjunctivitis conjunctival | #1 |
| bromfenac sodium | #1 |
| eye wash | #1 |
| improvement combinedtreatment | #1 |
| conjunctivitis enrolled | #1 |
| severe conjunctivitis eyes | #1 |
| keratoconjunctivitis male | #1 |
| subjective ocular symptoms | #1 |
| higher akc | #1 |
| bf concomitantly | #1 |
| vkc akc | #1 |
| conjunctivitis helper | #1 |
| tacrolimus ophthalmic | #1 |
| conjunctivitis seasonal | #1 |
| talymus | #1 |
| eyebon eye | #1 |
| vkc conclusions | #1 |
| instillation bromfenac | #1 |
| accuracy conjunctivitis | #1 |
| pge2 human conjunctival | #1 |
| sodium ophthalmic solution | #1 |
| therapy levocabastine | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| clinical signs akc | #1 |
| allergic tranilast | #1 |
| patients severe conjunctivitis | #1 |
| action child conjunctivitis | #1 |
| keratoconjunctivitis background | #1 |
| allerwatch diagnostic accuracy | #1 |
| dscg symptoms | #1 |
| hyperemia pain | #1 |
| patients atopic keratoconjunctivitis | #1 |
| commercial eyewash solutions | #1 |
| patients capilia | #1 |
| solution ocular | #1 |
| conjunctival fibroblasts production | #1 |
| dscg 005 | #1 |
| solution allergic | #1 |
| tacrolimus ophthalmic solution | #1 |
| patients akc | #1 |
| dscg fml | #1 |
| samples allergic conjunctivitis | #1 |
| ocular allergic diseases | #1 |
| eye itching | #1 |
| commercial washing solution | #1 |
| binocular conjunctivitis | #1 |
| levocabastine artificial tears | #1 |
| severe akc | #1 |
| production tranilast | #1 |
| il4 causing | #1 |
| sodium bf | #1 |
| severe binocular conjunctivitis | #1 |
| diseases tear | #1 |
| dha il4 | #1 |
| keratoconjunctivitis vernal | #1 |
| conjunctivitis including | #1 |
| allerwatch positivity rate | #1 |
| 01 tacrolimus eye | #1 |
| prostaglandin tears | #1 |
| akc vkc | #1 |
| washing allergens | #1 |
| postoperative conjunctivitis | #1 |
| radioimmunoassay il4 | #1 |
| bf fml | #1 |
| drops elicited | #1 |
| allerwatch tests | #1 |
| dscg bf | #1 |
| akc vernal | #1 |
| rapid ophthalmic | #1 |
| iop akc | #1 |
| 10 objective signs | #1 |
| systemic control pain | #1 |
| dha western blotting | #1 |
| akc tear | #1 |
| adeno eye | #1 |
| eotaxin1 production | #1 |
| il4 tear | #1 |
| vkc april | #1 |
| characterized conjunctival | #1 |
| keratoconjunctivitis akc | #1 |
| signs palpebral | #1 |
| suppressing pge2 production | #1 |
| adenovirus capilia | #1 |
| selective chemotactic effects | #1 |
| exacerbation vkc | #1 |
| production conjunctival fibroblasts | #1 |
| eyewash solution | #1 |
| eyewash | #1 |
| tacrolimus eye drops | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| allergic conjunctivitis | #1 |
| tacrolimus eye treatment | #1 |
| allergic conjunctivitis drop | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| allergic postoperative | #1 |
| fml dscg | #1 |
| akc treatment | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| fluorometholone 002 | #1 |
| 3 months signs | #1 |
| keratocytes tnfα | #1 |
| higher capilia | #1 |
| tacrolimus ophthalmic suspension | #1 |
| eyewash solution bak | #1 |
| ded anti | #1 |
| fml patients | #1 |
| commercial eyewash | #1 |
| eyewash solutions | #1 |
| inhibition eotaxin1 | #1 |
| conjunctivitis japanese | #1 |
| corneal epithelium disorders | #1 |
| experience 01 | #1 |
| nsaids systemic control | #1 |
| include conjunctival | #1 |
| allergic corneal | #1 |
| fml 002 | #1 |
| tranilast eotaxin1 | #1 |
| fourgraded severity | #1 |
| positivity rate allerwatch | #1 |
| fml administered | #1 |
| conjunctivitis treated | #1 |
| child conjunctivitis | #1 |
| allergenmediated conjunctivitis | #1 |
| eye allerwatch | #1 |
| stat6results | #1 |
| cd3 cd4bearing cells | #1 |
| compared fluorometholone | #1 |
| cedrus conjunctivitis | #1 |
| il4 tranilast | #1 |
| epithelium disorders | #1 |
| bak epithelium | #1 |
| instillation symptoms | #1 |
| initiating tacrolimus | #1 |
| akc patients | #1 |
| tears conjunctival fibroblasts | #1 |
| concomitant bf | #1 |
| tacrolimus eye drop | #1 |
| adverse events scores | #1 |
| allergic docosahexaenoic | #1 |
| itching levocabastine | #1 |
| capilia adeno eye | #1 |
| initiation tacrolimus treatment | #1 |
| scores hyperemia | #1 |
| drop levocabastine | #1 |
| selected fml | #1 |
| adult cedrus conjunctivitis | #1 |
| tears allergic | #1 |
| scleritis tacrolimus | #1 |
| efficacy bromfenac sodium | #1 |
| production ketotifen fumarate | #1 |
| test capilia | #1 |
| cobblestonelike papillae | #2 |
| female humans akc | #2 |
| seasonal allergic conjunctivitis | #2 |
| patients severe akc | #2 |
| tears thiazolidines | #2 |
| factor vkc | #2 |
| defined conjunctival | #2 |
| tacrolimus 1 month | #2 |
| disease antiallergic | #2 |
| papillary excision | #2 |
| treated bromfenac | #2 |
| drops conjunctival | #2 |
| talymus akc | #2 |
| pollutants prevalence | #2 |
| baseline papillae | #2 |
| effects topical tacrolimus | #2 |
| steroid metaregression | #2 |
| oral ari | #2 |
| aided papillary | #2 |
| endpoint itching scale | #2 |
| akc young adult | #2 |
| ketotifen dexamethasone | #2 |
| conjunctival injection edema | #2 |
| steroids epitheliopathy | #2 |
| score topical | #2 |
| nonpreserved eyewash solution | #2 |
| eosinophils corneal damage | #2 |
| study designopen cohort | #2 |
| formation akc | #2 |
| vkc japan | #2 |
| lacrimation objective | #2 |
| papillae akc | #2 |
| atopic diagnostic techniques | #2 |
| conjunctivitis retrospective | #2 |
| including akc | #2 |
| corneal lesions | #2 |
| benzophenones bromobenzenes | #2 |
| test papillae | #2 |
| conjunctival injection reduction | #2 |
| epitheliopathy steroids | #2 |
| tear ige correlation | #2 |
| environmental studies prevalence | #2 |
| cytodiagnosis dermatitis | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| elasticity eyelid | #2 |
| treatment ecp concentrations | #2 |
| iop topical steroids | #2 |
| selected bf | #2 |
| 18 akc | #2 |
| folliculosis papillae | #2 |
| period rhodanine | #2 |
| conjunctivitis proliferative | #2 |
| tacrolimus topical | #2 |
| epinastine 15 minutes | #2 |
| tear film layer | #2 |
| tacrolimus detection | #2 |
| proliferative called | #2 |
| drop concomitantly | #2 |
| sodium bromfenac | #2 |
| shield ulcers patients | #2 |
| corneal epitheliopathy | #2 |
| tacrolimus 12 weeks | #2 |
| ophthalmic nsaid | #2 |
| conjunctiva bulbar | #2 |
| bromfenac effective | #2 |
| suspension talymus | #2 |
| atopic blepharitis | #2 |
| akc 10 | #2 |
| drops hyperemia | #2 |
| 001 brush | #2 |
| severity corneal lesions | #2 |
| tacrolimus detection limit | #2 |
| lessen steroid | #2 |
| adjustments epitheliopathy score | #2 |
| lesions allergic | #2 |
| ensured proving | #2 |
| asthma heart diseases | #2 |
| drop steroid | #2 |
| edema height | #2 |
| epitheliopathy shield | #2 |
| deqs tear | #2 |
| ecp severity markers | #2 |
| excision cobblestone | #2 |
| drops refractory | #2 |
| epinastine superiority | #2 |
| unpaired ttest talymus | #2 |
| correlation fluorescein | #2 |
| brush cytology samples | #2 |
| prevalence akc | #2 |
| akc patients correlation | #2 |
| adjustments epitheliopathy | #2 |
| eyes 824 | #2 |
| akc 10 eyes | #2 |
| control subjects eyes | #2 |
| muc16 immunohistochemistry | #2 |
| oral aldose | #2 |
| ari ocular | #2 |
| eyelid elasticity | #2 |
| severity corneal complications | #2 |
| tacrolimus published data | #2 |
| papillae preventing | #2 |
| month eyewash | #2 |
| conjunctival findings severity | #2 |
| tacrolimus iop | #2 |
| mucin analyzed | #2 |
| papillae severe | #2 |
| corneal lesions regrowth | #2 |
| post cataract surgery | #2 |
| premedication combined | #2 |
| signs decreased | #2 |
| conjunctivitis adolescent | #2 |
| conjunctivitis condition | #2 |
| noninferiority olopatadine | #2 |
| metaregression analysis glaucoma | #2 |
| topical antiallergic agents | #2 |
| brush cytology patients | #2 |
| scores tacrolimus | #2 |
| solution epinastine | #2 |
| tacrolimus shield | #2 |
| dryness scores | #2 |
| complain foreign | #2 |
| allergic conjunctivitis levocabastine | #2 |
| total signs symptoms | #2 |
| allergic conjunctivitis akc | #2 |
| conjunctivitis 10 | #2 |
| betamethasone glaucoma | #2 |
| normal blinking patients | #2 |
| corneal epitheliopathy score | #2 |
| bovine entericcoated lactoferrin | #2 |
| improvement corneal fluorescein | #2 |
| severe allergic conjunctivitis | #2 |
| treatment shield ulcer | #2 |
| rhodanine rose | #2 |
| accompanied subjective | #2 |
| corneal findings | #2 |
| edema corneal damage | #2 |
| corneal temperature patients | #2 |
| ulcer complain | #2 |
| reported eotaxin | #2 |
| efficacy severe akc | #2 |
| corneal epithelial signs | #2 |
| corneal recurrences | #2 |
| lid skin | #2 |
| patients tacrolimus eye | #2 |
| formation palpebral | #2 |
| sem575 quantitatively | #2 |
| nonwash | #2 |
| elevation tacrolimus | #2 |
| total clinical signs | #2 |
| tacrolimus lessen | #2 |
| largescale study protocol | #2 |
| tears akc | #2 |
| height papillae | #2 |
| allergic diagnosis | #2 |
| objective signs baseline | #2 |
| decrease corneal temperature | #2 |
| keratoconjunctivitis age | #2 |
| tarsal brush | #2 |
| treatment total signs | #2 |
| conjunctivitis purpose | #2 |
| papilla accompanied | #2 |
| diathesis subjective | #2 |
| 1 month tacrolimus | #2 |
| conjunctivitis representative | #2 |
| oral ari ono2235 | #2 |
| olopatadine cedar | #2 |
| elasticity severity | #2 |
| epitheliopathy refractory | #2 |
| correlation neutrophils | #2 |
| sem575 clinical | #2 |
| neutrophils corneal damage | #2 |
| treatment atopic blepharitis | #2 |
| concomitantly abovementioned | #2 |
| giant papillary formation | #2 |
| adjuvant fluorometholone | #2 |
| improvement vital staining | #2 |
| cornea grading | #2 |
| mucous discharge severity | #2 |
| tacrolimus tonometry | #2 |
| detected akc | #2 |
| conjunctivitis epitheliopathy | #2 |
| evaluate superiority | #2 |
| epitheliopathy corneal | #2 |
| 062 tear | #2 |
| patients shield ulcers | #2 |
| akc 1 | #2 |
| refractory allergic | #2 |
| solutions japan | #2 |
| conclusions bromfenac | #2 |
| adjuvant betamethasone | #2 |
| topical tacrolimus combination | #2 |
| skin elasticity patients | #2 |
| conjunctiva atopic | #2 |
| immunoregulatory effects study | #2 |
| bromfenac sodium bromfenac | #2 |
| akc adolescent | #2 |
| giant papillae formation | #2 |
| signs blood concentration | #2 |
| dermatitis remission | #2 |
| mmc aided | #2 |
| effects tacrolimus | #2 |
| neutrophils brush | #2 |
| keratoconjunctivitis corneal | #2 |
| conventional antiallergic drugs | #2 |
| adjuvant fluorometholone 95 | #2 |
| cutometer sem575 | #2 |
| lower conjunctival sacs | #2 |
| simple papillary resection | #2 |
| corneal ulcers patients | #2 |
| epitheliopathy score | #2 |
| production specular | #2 |
| akc treated | #2 |
| severity eyelid | #2 |
| bromfenac ophthalmic solution | #2 |
| resolution thermography | #2 |
| conjunctiva papillary | #2 |
| oral ari administration | #2 |
| cedrus conjunctiva | #2 |
| fluorescein conjunctival injection | #2 |
| eyelid atopic | #2 |
| akc adult | #2 |
| methods thirtysix patients | #2 |
| score adjustments | #2 |
| limbal swelling | #2 |
| representative subjective | #2 |
| corneal damage patients | #2 |
| regrowth papillae | #2 |
| papillae mucous discharge | #2 |
| corneal complications height | #2 |
| eyewash 005 | #2 |
| akc 6 | #2 |
| papillae limbus | #2 |
| akc aureus | #2 |
| cac test | #2 |
| administered elf bovine | #2 |
| vkc 5 | #2 |
| papillary formation | #2 |
| hyperemia lacrimation | #2 |
| akc levels | #2 |
| swelling folliculosis | #2 |
| inflammatory child child | #2 |
| recurrence corneal lesions | #2 |
| based papillae | #2 |
| allergic endophthalmitis | #2 |
| excision cobblestonelike papillae | #2 |
| scores papillary | #2 |
| superiority epinastine | #2 |
| plaques 791 | #2 |
| correlation eosinophils | #2 |
| 2helper cell | #2 |
| patients shield | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| mmc 7 eyes | #2 |
| olopatadine ocular | #2 |
| sem575 | #2 |
| simple resection regrowth | #2 |
| administered elf | #2 |
| diabetic patients ono2235 | #2 |
| serum allergic parameters | #2 |
| eyelid skin elasticity | #2 |
| conjunctival corneal cells | #2 |
| corneal damage height | #2 |
| epitheliopathy patients | #2 |
| pge2 tears | #2 |
| eyes betamethasone | #2 |
| diagnosis ensured | #2 |
| akc sac patients | #2 |
| recurrence corneal complications | #2 |
| ecp levels akc | #2 |
| treatment tear | #2 |
| aureussecreted enterotoxins | #2 |
| akc allergic diagnosis | #2 |
| suspension lactoferrin | #2 |
| epinastine ophthalmic solution | #2 |
| bovine placebo | #2 |
| air pollutants prevalence | #2 |
| patients corneal ulcers | #2 |
| japan topical tacrolimus | #2 |
| administration specular | #2 |
| ocular surface mucin | #2 |
| allergic conjunctivitis ige | #2 |
| severity corneal damage | #2 |
| extents corneal | #2 |
| ceramide gel application | #2 |
| sac healthy | #2 |
| regrowth 7 eyes | #2 |
| eyelid atopic dermatitis | #2 |
| sodium ophthalmic | #2 |
| blepharitis ceramides | #2 |
| lactoferrin 01 | #2 |
| japan topical | #2 |
| japan akc | #2 |
| olopatadine visit | #2 |
| csa akc | #2 |
| allergy accompanied | #2 |
| placebo noninferiority | #2 |
| 95 adjuvant betamethasone | #2 |
| association outpatient attendance | #3 |
| severe allergic patients | #3 |
| conjunctivitis benzamidines | #3 |
| outpatient visits august | #3 |
| 21 akc patients | #3 |
| ebv ade | #3 |
| allergic postsurgical | #3 |
| benzamidine par2 | #3 |
| ophthalmic solution placebo | #3 |
| diseases acds | #3 |
| eye cooling | #3 |
| healed amniotic | #3 |
| treatment vernal | #3 |
| autumnal pollen | #3 |
| muc1 brush cytology | #3 |
| pilocarpine visante | #3 |
| scale tmh | #3 |
| sdedry eye | #3 |
| histamine specimens | #3 |
| reaction conjunctiva | #3 |
| dfna eye | #3 |
| periostin comorbidities | #3 |
| oct graticule | #3 |
| child conjunctiva | #3 |
| permeability postoperatively | #3 |
| par2 cultured | #3 |
| existence par2 mrna | #3 |
| tryptase increases | #3 |
| fluorescein glycyrrhizic | #3 |
| akc higher | #3 |
| allergic cornea | #3 |
| allergic corneal diseases | #3 |
| 01 ophthalmic | #3 |
| uncontrollable glaucoma | #3 |
| 22 eyes 100 | #3 |
| flare metry | #3 |
| metry dfna | #3 |
| patching patient | #3 |
| insufficient tear supply | #3 |
| tear il13 | #3 |
| conjunctivitis pm25 | #3 |
| alterations tear | #3 |
| akc eyes | #3 |
| topical cyclosporine 01 | #3 |
| outpatient attendance july | #3 |
| evaluate tear | #3 |
| severe allergy patients | #3 |
| corneal ulceration role | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| vkc long | #3 |
| aged biological dressings | #3 |
| strip meniscometry testing | #3 |
| nbs normal eyes | #3 |
| efficacy bromfenac | #3 |
| fibronectin normal controls | #3 |
| signs remission | #3 |
| superficial cells conjunctiva | #3 |
| pm25 outpatient attendance | #3 |
| laser flarecellmetry | #3 |
| insensible administration insensible | #3 |
| akc tear periostin | #3 |
| tears adolescent | #3 |
| par2 benzamidines blotting | #3 |
| fibers lnfs | #3 |
| dscg administration | #3 |
| conjunctival corneal | #3 |
| diabetic corneal disease | #3 |
| dramatic healing | #3 |
| superior limbic portion | #3 |
| temperature evaluate | #3 |
| pollen august | #3 |
| akc comorbidities | #3 |
| akc periostin | #3 |
| sensitivity tear | #3 |
| treatment strip meniscometry | #3 |
| eye washing | #3 |
| papillae morphometric | #3 |
| sde controls | #3 |
| macroerosions | #3 |
| akc rose bengal | #3 |
| oct tmh | #3 |
| 1 month initiation | #3 |
| allergic patients conjunctivitis | #3 |
| akc alterations | #3 |
| cells brush cytology | #3 |
| allerwatch | #3 |
| phenomena tacrolimus | #3 |
| 5ac mrna | #3 |
| injections keratoconjunctivitis | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| 01 bromfenac | #3 |
| lamp device | #3 |
| proving type | #3 |
| dibenzoxepins female | #3 |
| samples correlate | #3 |
| aureus akc patients | #3 |
| antiallergic eye drop | #3 |
| eyes control subjects | #3 |
| cell flare count | #3 |
| cholinergic treatment response | #3 |
| vkc 5 eyes | #3 |
| measurements schirmer | #3 |
| induced inflammation lenses | #3 |
| papillae upper | #3 |
| histamine conjunctival cells | #3 |
| surgery dfna | #3 |
| conjunctiva conjunctivitis | #3 |
| rtpcr par2 | #3 |
| cornea atopic | #3 |
| adedry eye | #3 |
| ulcer persistent | #3 |
| aged elisa | #3 |
| antibody titers ade | #3 |
| increased comfort | #3 |
| elisa histamine | #3 |
| antieaigg | #3 |
| ari corneal | #3 |
| conjunctiva allergic | #3 |
| ophthalmic solution nsaid | #3 |
| 005 collagens | #3 |
| sligkv examined | #3 |
| akc persistent | #3 |
| keratoconjunctivitis vkc | #3 |
| 13 eyes 69 | #3 |
| 3 sjögrens syndrome | #3 |
| pretreatment docosahexaenoic acid | #3 |
| prospectively diclofenac | #3 |
| vkc eyes | #3 |
| nuclei vkc | #3 |
| akc serum periostin | #3 |
| vkc relevant factor | #3 |
| decline corneal | #3 |
| histamine cedar | #3 |
| formation vernal | #3 |
| periostin topical | #3 |
| protein conjunctival fibroblasts | #3 |
| cases vkc | #3 |
| 12 akc | #3 |
| production conjunctival | #3 |
| diclofenac epithelium | #3 |
| nbs subbasal | #3 |
| epinastine placebo | #3 |
| hyperemia allergic | #3 |
| interleukin4 tacrolimus | #3 |
| vkc levels | #3 |
| underwent periodic | #3 |
| conjunctival fibroblasts tryptase | #3 |
| papillary resection | #3 |
| weekly average values | #3 |
| giant papilla | #3 |
| commercial washing | #3 |
| higher muc1 eyes | #3 |
| postsurgical conjunctivitis | #3 |
| superior keratoconjunctiva | #3 |
| 005 mmc | #3 |
| tear periostin biomarker | #3 |
| 21 akc | #3 |
| scored global | #3 |
| fibronectin vkc | #3 |
| cooling cataract | #3 |
| eyes vkc | #3 |
| pollen postoperative | #3 |
| membrane uncontrollable | #3 |
| fluorescein scale | #3 |
| existence par2 | #3 |
| lacrimal punctal occlusion | #3 |
| ocular surface diabetes | #3 |
| local tear deficiency | #3 |
| techniques conjunctivitis | #3 |
| titers ade | #3 |
| infrared radiation thermography | #3 |
| rose bengal akc | #3 |
| 005 ophthalmic solution | #3 |
| allergic conjunctivitis aged | #3 |
| 5ac brush | #3 |
| histamine cedar pollen | #3 |
| technique uncontrollable | #3 |
| eosinophils corneal | #3 |
| tryptase conjunctiva | #3 |
| tear periostin | #3 |
| techniques tears | #3 |
| interleukin4 histamine | #3 |
| akc biomarkers | #3 |
| dry eye eye | #3 |
| il1beta th2 | #3 |
| july pm25 | #3 |
| vkc papillae | #3 |
| periostin akc | #3 |
| differences dfna | #3 |
| healing allergic | #3 |
| icecold eye mask | #3 |
| akc atopic dermatitis | #3 |
| mmcaided papillary resection | #3 |
| ecp severity | #3 |
| patients tmh measurements | #3 |
| conjunctival disease | #3 |
| normal controls collagens | #3 |
| vkc exacerbation | #3 |
| cytology impression | #3 |
| ulcers plaques | #3 |
| technique 2 eyes | #3 |
| prophylaxis conjunctival | #3 |
| eyes akc | #3 |
| allergic corneal ulcer | #3 |
| tears treatment | #3 |
| conjunctivitis lymphocytes | #3 |
| inflammation mmc | #3 |
| nonpreserved artificial tears | #3 |
| immunosuppressive eye | #3 |
| tmh measurement | #3 |
| study cutometer | #3 |
| conjunctivitis allergic | #3 |
| 111 177 | #3 |
| akc higher muc1 | #3 |
| improvement squamous metaplasia | #3 |
| tear periostin comorbidities | #3 |
| pm25 allergic | #3 |
| tissue remodeling exacerbation | #3 |
| relevant factor exacerbation | #3 |
| papillary regrowth | #3 |
| drop selected | #3 |
| epithelium adverse | #3 |
| eyes allergic | #3 |
| 12 akc patients | #3 |
| treatment skin elasticity | #3 |
| erosions refractory | #3 |
| ulcer akc | #3 |
| drops treat | #3 |
| vkc differences | #3 |
| cultured tryptase | #3 |
| dfna eye dfna | #3 |
| tear periostin patients | #3 |
| corneal complications1 | #3 |
| solutions prospective | #3 |
| lnfs nbs | #3 |
| lower muc5ac | #3 |
| akc confocal | #3 |
| underwent staining | #3 |
| akc dyes humans | #3 |
| vkc fibronectin | #3 |
| cell metry | #3 |
| dfna diclofenac epithelium | #3 |
| keratoconjunctivitis leupeptins | #3 |
| dfna control | #3 |
| mmc authors | #3 |
| hydrochloride 01 | #3 |
| mmc excision | #3 |
| thermography evaluate | #3 |
| patching case | #3 |
| formation vkc | #3 |
| vivo corneal akc | #3 |
| il1beta th2 cytokines | #3 |
| operation eye | #3 |
| histamine superficial cells | #3 |
| vkc sac | #3 |
| patients pilocarpine tablets | #3 |
| portable recordable | #3 |
| central corneal temperature | #3 |
| corneal epithelial structure | #3 |
| traumatic swelling | #3 |
| cases vernal | #3 |
| treatment oral pilocarpine | #3 |
| healing dramatic healing | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| ssdry | #3 |
| 5 eyes akc | #3 |
| insufficient tear | #3 |
| corneal akc | #3 |
| diclofenac eye drops | #3 |
| ulcers eyes | #3 |
| laser cellflaremetry | #3 |
| outpatient visits july | #3 |
| conjunctivitis negative | #3 |
| vkc cell | #3 |
| glaucoma amniotic | #3 |
| akc confocal microscopy | #3 |
| samples immunocytochemical | #4 |
| 0001 brush | #4 |
| photophobia diagnosis | #4 |
| pcr epithelial | #4 |
| clinical conjunctival | #4 |
| corneal temperature blink | #4 |
| steroids iop | #4 |
| hydrochloride ophthalmic | #4 |
| noninfectious necrotizing | #4 |
| recordable slit | #4 |
| muc16 muc5ac alterations | #4 |
| simple resection | #4 |
| thinoptx acrysof | #4 |
| severe vkc patients | #4 |
| ocular surface epithelial | #4 |
| drop artificial tears | #4 |
| portable slit | #4 |
| allergic conjunctival | #4 |
| underwent corneal | #4 |
| 2 4 alterations | #4 |
| conjunctiva density | #4 |
| 33 chemokines | #4 |
| compared vkc | #4 |
| pgd2 normal volunteers | #4 |
| akc crth2 expression | #4 |
| studied corneal | #4 |
| mucin mucins tears | #4 |
| vkc normal controls | #4 |
| tomography tear | #4 |
| epithelial cells rsv | #4 |
| allergic patients elisa | #4 |
| akc healthy | #4 |
| formation conjunctivitis | #4 |
| il4 tears | #4 |
| surface conjunctival | #4 |
| cytology goblet | #4 |
| sio2 20 | #4 |
| eye wash solution | #4 |
| acds conventional | #4 |
| conjunctivitis ige | #4 |
| subjects muc5ac | #4 |
| fva treatment | #4 |
| tacrolimus conclusions | #4 |
| mucins tears mucin | #4 |
| tablets tears | #4 |
| histamine h1 antagonist | #4 |
| metaregression analysis effects | #4 |
| conjunctival proliferative | #4 |
| grade dry eye | #4 |
| chemotaxis conjunctiva | #4 |
| akcaffected patients | #4 |
| 10 seconds temperature | #4 |
| sterilized asian dust | #4 |
| greater 3 grade | #4 |
| sterilized asian | #4 |
| 3004 respondents | #4 |
| allergic epidemiologic studies | #4 |
| temperature corneal | #4 |
| cultured conjunctival | #4 |
| solutions piperidines | #4 |
| defensins conjunctivitis | #4 |
| patient atopic keratoconjunctivitis | #4 |
| allergic conjunctival diseases | #4 |
| lower tear function | #4 |
| controls brush cytology | #4 |
| corneal ulcers eyes | #4 |
| epinastine hydrochloride | #4 |
| assay pgd2 | #4 |
| tears patients | #4 |
| include ocular | #4 |
| proteinchip array elisa | #4 |
| steroids fluorometholone | #4 |
| male ophthalmic | #4 |
| 061 028 degree | #4 |
| untreated asian dust | #4 |
| sensitization asian dust | #4 |
| dust wheal | #4 |
| eosinophil toxic activity | #4 |
| greater concentrations tears | #4 |
| akc sac | #4 |
| atopic ocular | #4 |
| exponential equation inclination | #4 |
| epithelial muc | #4 |
| erosion shield | #4 |
| disease akc | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| performed tears | #4 |
| thermography anterior | #4 |
| staining ocular | #4 |
| rsv allergic reaction | #4 |
| tears pathogenesis | #4 |
| ulcers mucin | #4 |
| akc chemotaxis | #4 |
| pathogenesis noninfectious | #4 |
| 2010 allergic | #4 |
| 34 15 seconds | #4 |
| epithelial disease eyes | #4 |
| specimens underwent | #4 |
| aged rose | #4 |
| july pollen | #4 |
| completely severe | #4 |
| keratoconjunctivitis purpose | #4 |
| primary sources chemokines | #4 |
| genes conjunctival | #4 |
| topical oral steroids | #4 |
| muc16 goblet | #4 |
| level conjunctiva | #4 |
| alterations atopic | #4 |
| eyes epithelial disease | #4 |
| acuity akc | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| patients topical cyclosporine | #4 |
| blinding purpose | #4 |
| ulcers atopic | #4 |
| cytometry mild | #4 |
| bromfenac ophthalmic | #4 |
| tear function test | #4 |
| epithelial disease patients | #4 |
| bengal sensation | #4 |
| eyes akc patients | #4 |
| implantation rollable | #4 |
| tryptase dose | #4 |
| cytometry mild cases | #4 |
| placebo ophthalmic | #4 |
| conjunctivitis vkc | #4 |
| pgd2dependent migration eosinophils | #4 |
| rsv conjunctival epithelium | #4 |
| epithelial muc16 | #4 |
| epithelial pge2 production | #4 |
| akc healthy individuals | #4 |
| eyes corneal ulcers | #4 |
| eye operation | #4 |
| limbal grafts | #4 |
| corneal ulcers muc5ac | #4 |
| acds ophthalmologists | #4 |
| akc immunologic receptors | #4 |
| insignificant epithelial disease | #4 |
| ulcers control subjects | #4 |
| eosinophils receptor crth2 | #4 |
| eye sjögrens syndrome | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| patient eyes fluorescein | #4 |
| allergic conjunctivitis rsv | #4 |
| sensation tears | #4 |
| samples histocytological | #4 |
| interleukin2 tears | #4 |
| topical 01 tacrolimus | #4 |
| ocular allergic disease | #4 |
| goblet cell muc5ac | #4 |
| akc crth2 | #4 |
| severe ocular allergies | #4 |
| conjunctivitis methods | #4 |
| ari ono2235 | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| folliculosis | #4 |
| allergic fibroblasts | #4 |
| corneal temperature eye | #4 |
| lesions regrowth | #4 |
| staining muc | #4 |
| eyes sac | #4 |
| ige conjunctival | #4 |
| hypersensitivity mucin | #4 |
| correlation outpatient | #4 |
| levocabastine h1 | #4 |
| atopic dermatitis remission | #4 |
| eyes thinoptx | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| fibroblasts primary sources | #4 |
| atopic ocular allergies | #4 |
| controls interferometry | #4 |
| keratoconjunctivitis lacrimal | #4 |
| ophthalmologists evaluated | #4 |
| surface muc5ac | #4 |
| thinoptx intraocular | #4 |
| defensins greater | #4 |
| giemsas staining | #4 |
| sac control eyes | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| conjunctival papillary | #4 |
| interferometry grade | #4 |
| interferometry lipids | #4 |
| patients severe vkc | #4 |
| individuals pgd2 | #4 |
| vkc 4 | #4 |
| allergies blinding | #4 |
| akc pgd2dependent migration | #4 |
| p0001 impression | #4 |
| healthy individuals rtpcr | #4 |
| rose bengal scores | #4 |
| akc rtpcr | #4 |
| allergic conjunctival disease | #4 |
| inflammation akc | #4 |
| muc5ac brush | #4 |
| tear temperature | #4 |
| cornea grading scale | #4 |
| cell muc5ac | #4 |
| par2 mrna protein | #4 |
| allergic cytological | #4 |
| stimulation chemokine expression | #4 |
| thinoptx lens | #4 |
| atopic vernal | #4 |
| crth2 akc | #4 |
| trantas | #4 |
| implantation thinoptx | #4 |
| conjunctivitis levels | #4 |
| staining muc16 | #4 |
| patients epithelial disease | #4 |
| scores conjunctival | #4 |
| p0001 brush | #4 |
| muc5ac brush cytology | #4 |
| deqs scores | #4 |
| vmr 3 months | #4 |
| corneal safety | #4 |
| excision papillary | #4 |
| lower tear clearance | #4 |
| fungi epidemiologic studies | #4 |
| papillae normal | #4 |
| cells lnfs | #4 |
| highrisk glaucoma patients | #4 |
| interferometry controls | #4 |
| ophthalmologists eye drops | #4 |
| infected conjunctival | #4 |
| immunologic receptors akc | #4 |
| treatment vmr values | #4 |
| interferometry 2 | #4 |
| sac grade | #4 |
| tear function patients | #4 |
| ded 1 | #4 |
| diameter allergen | #4 |
| moisture checker | #4 |
| eyes ulcers | #4 |
| corneal sensitivity measurements | #4 |
| 020 013 | #4 |
| insignificant epithelial | #4 |
| adolescent betamethasone | #4 |
| conventional portable | #4 |
| corneal sensitivity measurement | #4 |
| eotaxin1 rantes | #4 |
| membrane patching | #4 |
| tears 10 patients | #4 |
| rejection limbal | #4 |
| mucins 1 | #4 |
| chemokine genes fibroblasts | #4 |
| microscope evaluating | #4 |
| treatment vmr | #4 |
| thinoptx | #4 |
| cases sufficient examination | #4 |
| muc5ac mrna expression | #4 |
| muc1 2 | #4 |
| dscg day | #4 |
| crth2 peripheral | #4 |
| thermometer 20 | #4 |
| bromfenac eye drops | #4 |
| 4 chemokines stimulation | #4 |
| vkc messenger reverse | #4 |
| vkc male receptors | #4 |
| months papillary | #4 |
| controls interferometry grade | #4 |
| tnfalpha30ng | #4 |
| rsv conjunctiva | #4 |
| eyes insignificant | #4 |
| special brush | #4 |
| levocabastine ophthalmic | #4 |
| persistent 6 | #4 |
| diseases portable | #4 |
| muc5ac alterations | #4 |
| weeks vital | #4 |
| samples allergic | #4 |
| wilcoxon signed test | #4 |
| metaplasia reduction | #4 |
| oedema papillary | #4 |
| pgd2dependent migration | #4 |
| 18 akc patients | #4 |
| asian dust extract | #4 |
| eyes video | #4 |
| conjunctiva differences | #4 |
| papillae giant | #4 |
| treatment dryeye symptoms | #5 |
| vcam1 fibroblasts | #5 |
| alterations ocular | #5 |
| anterior fluorometry | #5 |
| tears received | #5 |
| inflammatory cells hel | #5 |
| eosinophil adhesion fibroblasts | #5 |
| conjunctiva dermatitis | #5 |
| histamine superficial | #5 |
| diclofenac eye | #5 |
| 376±56 years | #5 |
| allergic conjunctivitis patients | #5 |
| stimulated conjunctival | #5 |
| hel cytokines | #5 |
| adhered corneal | #5 |
| pretreatment dha | #5 |
| solutions pollen | #5 |
| allergic drug therapy | #5 |
| adolescent conjunctivitis | #5 |
| vkc atopic | #5 |
| hel akc | #5 |
| eye warmer | #5 |
| dryeye symptoms treatment | #5 |
| akc ecp | #5 |
| postsurgical inflammation | #5 |
| treatment tacrolimus ointment | #5 |
| solution olopatadine | #5 |
| layer mgd | #5 |
| corneal fibroblasts icam1 | #5 |
| eosinophils activated fibroblasts | #5 |
| 20 sio2 | #5 |
| pgd2 normal | #5 |
| measurements strip | #5 |
| scans akc | #5 |
| punctal occlusion oct | #5 |
| conjunctival lipid | #5 |
| scores expressibility | #5 |
| akc hel | #5 |
| array chemotaxis | #5 |
| stained conjunctival | #5 |
| ihc conjunctival inflammation | #5 |
| inflammation mitomycin | #5 |
| severe stevensjohnson syndrome | #5 |
| severity akc | #5 |
| cytokinestimulation | #5 |
| lipid oxidation hel | #5 |
| human conjunctival fibroblasts | #5 |
| worse akc | #5 |
| akc disease | #5 |
| allergic female | #5 |
| study epinastine | #5 |
| thinoptx iol | #5 |
| lesion corneal | #5 |
| eye circulating | #5 |
| visits august | #5 |
| month tear | #5 |
| accompanying allergic | #5 |
| fibroblasts eosinophil adherence | #5 |
| trantas dots | #5 |
| topical cyclosporine therapy | #5 |
| pm25 outpatient | #5 |
| 01 mcfg | #5 |
| case corneal ulcer | #5 |
| asthenopia dry | #5 |
| impression brush | #5 |
| 15 minutes dose | #5 |
| ulcers controls | #5 |
| hne ihc | #5 |
| females akc | #5 |
| akc normal subjects | #5 |
| temperature blink | #5 |
| controls ebv | #5 |
| wilcoxonmatched pair test | #5 |
| eosinophil adherence fibroblasts | #5 |
| ocular surface disorder | #5 |
| younger age effects | #5 |
| akc patients study | #5 |
| intraoperative mitomycin excision | #5 |
| akc acinar | #5 |
| endophthalmitis eosinophils | #5 |
| fibroblasts fibroblast damage | #5 |
| ocular anesthesia | #5 |
| antifungal mcfg | #5 |
| samples akc | #5 |
| 310±165 years | #5 |
| conjunctivitis pollen | #5 |
| treatment epinastine | #5 |
| mitomycin excision | #5 |
| upper palpebral | #5 |
| hel ihc | #5 |
| diseases required | #5 |
| conjunctiva mmc | #5 |
| disposable eyelid | #5 |
| bengal suture | #5 |
| 329±57 years | #5 |
| thiazolidines administration | #5 |
| akc laser | #5 |
| keratoconjunctivitis objective | #5 |
| supernatants conjunctival | #5 |
| 7 conjunctival | #5 |
| crth2 eosinophils | #5 |
| simple papillary | #5 |
| damaged eosinophil | #5 |
| signs akc | #5 |
| 3 cases followup | #5 |
| visits july | #5 |
| local tear | #5 |
| 0001 strip | #5 |
| cases tests | #5 |
| dryeye symptoms | #5 |
| warmer improved | #5 |
| age 9 ± | #5 |
| corneal involvement | #5 |
| il4 histamine | #5 |
| staining muc5ac | #5 |
| injection conjunctival | #5 |
| cornea explain | #5 |
| ocular allergic | #5 |
| lower atopic | #5 |
| oct lower | #5 |
| vkc iop | #5 |
| conjunctival allergen | #5 |
| treatment shield | #5 |
| severe conjunctivitis | #5 |
| impression cytology samples | #5 |
| warmer applied | #5 |
| disposable eyelidwarming device | #5 |
| ulcer dermatitis | #5 |
| labeling surface akc | #5 |
| disease conjunctivitis | #5 |
| conjunctival inflammatory status | #5 |
| anterior scleritis patients | #5 |
| months amniotic | #5 |
| eye warmer treatment | #5 |
| ophthalmic test | #5 |
| accompanied varying | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| regulation allergic cornea | #5 |
| ophthalmic suspension | #5 |
| alpha allergic | #5 |
| keratoconjunctivitis giant | #5 |
| tnfα costimulation | #5 |
| schirmer1 test groups | #5 |
| damage impression | #5 |
| 5 females akc | #5 |
| cells vkc | #5 |
| status confocal | #5 |
| situ nickend regulation | #5 |
| 20 akc patients | #5 |
| controls inflammatory cells | #5 |
| stainings tear | #5 |
| bromobenzenes cornea | #5 |
| meniscus punctal | #5 |
| 005 schirmer1 | #5 |
| cornea cytodiagnosis | #5 |
| conjunctivitis prostaglandin | #5 |
| conventional steroid treatment | #5 |
| schiff immunohistochemical | #5 |
| 17 mgd patients | #5 |
| prostaglandin chemotaxis | #5 |
| conjunctival confocal microscopy | #5 |
| crth2 prostaglandin receptors | #5 |
| mcfg eye | #5 |
| allergic cyclosporine | #5 |
| eosinophils immunologic receptors | #5 |
| equipment dry | #5 |
| staining administration | #5 |
| allergic keratopathy | #5 |
| severe vernal | #6 |
| severe ocular inflammation | #6 |
| topical cys treatment | #6 |
| solution commercial | #6 |
| sac vkc | #6 |
| challenge cac | #6 |
| topical cys | #6 |
| ocular surface findings | #6 |
| antiallergic eye | #6 |
| eosinophil recruiting chemokines | #6 |
| defect penetrating | #6 |
| density conjunctival | #6 |
| extract sterilized | #6 |
| tbut vital | #6 |
| allergic diathesis | #6 |
| concomitant eye | #6 |
| examinations tear | #6 |
| tear stability values | #6 |
| dressings female | #6 |
| rose bengal dyes | #6 |
| tears xerophthalmia | #6 |
| elasticity cutometer | #6 |
| rate tbut | #6 |
| agents interferometry | #6 |
| symptoms vkc | #6 |
| coated elf | #6 |
| patients seldi | #6 |
| eosinophils crth2 | #6 |
| allergic conjunctivitis cac | #6 |
| fibroblasts conjunctival | #6 |
| allergens cedrus | #6 |
| corneal damage | #6 |
| rtpcr epithelial cells | #6 |
| dfna | #6 |
| instability conjunctival | #6 |
| conjunctivitis sac | #6 |
| severe vkc | #6 |
| 4 9 genes | #6 |
| syndrome tablets | #6 |
| evaporation vital | #6 |
| findings dry eye | #6 |
| fva landolt | #6 |
| bengal vital stainings | #6 |
| chloride eye | #6 |
| tryptase proliferation | #6 |
| july correlation | #6 |
| differences tear | #6 |
| oxidation hel | #6 |
| patients visante | #6 |
| obstructive mgd patients | #6 |
| tear meniscus patients | #6 |
| tear eosinophil | #6 |
| severe stevens | #6 |
| treatment tacrolimus | #6 |
| 4 muc | #6 |
| diseases periostin | #6 |
| hyperemia imidazoles | #6 |
| 20 pbs | #6 |
| schirmer1 test values | #6 |
| dermatitis scored | #6 |
| cyclosporine 01 | #6 |
| corneal fibroblasts pathogenesis | #6 |
| fluorometholone follow | #6 |
| papillae mucous | #6 |
| ade sde | #6 |
| grading tear | #6 |
| akc refractory | #6 |
| tacrolimus chronic | #6 |
| il4 il2r | #6 |
| signs scored | #6 |
| induced tear | #6 |
| edema severity | #6 |
| female fluorometholone | #6 |
| hyperemia swelling | #6 |
| specimens akc | #6 |
| conjunctival diseases | #6 |
| dust asian | #6 |
| ocular fatigue | #6 |
| conjunctival brush cytology | #6 |
| tear ecp | #6 |
| strip meniscometry scores | #6 |
| controlling eyelid | #6 |
| pcr muc5ac | #6 |
| cys ocular | #6 |
| pathogenesis ocular | #6 |
| atopic eyelids | #6 |
| levels air pollutants | #6 |
| functions topical | #6 |
| cgvhd improvements | #6 |
| eye evaluated | #6 |
| regulation benzamidines | #6 |
| scores goblet | #6 |
| ointment blood | #6 |
| defect ped | #6 |
| inflammatory cell densities | #6 |
| topical levocabastine | #6 |
| conjunctival confocal | #6 |
| intolerable irritation | #6 |
| tranilast inhibition | #6 |
| sde ade | #6 |
| betamethasone oral | #6 |
| eyes atopic | #6 |
| testing tear | #6 |
| levocabastine effective | #6 |
| tears acinar | #6 |
| itching conjunctival | #6 |
| treatment postoperative inflammation | #6 |
| corneal temperature | #6 |
| elevation refractory | #6 |
| akc vernal keratoconjunctivitis | #6 |
| remodeling vkc | #6 |
| samples underwent | #6 |
| ecp markers | #6 |
| upper tarsal conjunctiva | #6 |
| noninvasive suction device | #6 |
| twicedaily instillation | #6 |
| surgery cooling | #7 |
| revealed eosinophils | #7 |
| conjunctival inflammatory | #7 |
| conjunctival complications | #7 |
| conjunctival brush | #7 |
| superiority placebo | #7 |
| age 325 years | #7 |
| evaluation eyelid | #7 |
| development allergic conjunctivitis | #7 |
| patients comfort level | #7 |
| crth2 normal | #7 |
| mucins periodic | #7 |
| tears alpha | #7 |
| pathogenesis subsequent | #7 |
| ulcer corneal | #7 |
| nonparametric tears | #7 |
| chemotaxis eosinophils | #7 |
| increases proliferative | #7 |
| ocular inflammatory disorder | #7 |
| pge2 cox2 levels | #7 |
| administration fluorescein | #7 |
| eczema frequently | #7 |
| pgd2 dependent | #7 |
| sensation symptom | #7 |
| ulceration healthy | #7 |
| vkc gpc | #7 |
| tear supply | #7 |
| adult blepharitis | #7 |
| conclusion mmc | #7 |
| nerves tear | #7 |
| inhibitor ono2235 | #7 |
| tacrolimustreated eyes | #7 |
| cases preventing | #7 |
| status atopic | #7 |
| corneal lesion | #7 |
| gpc vkc | #7 |
| conjunctivitis risk | #7 |
| 4 tear | #7 |
| alpha tears | #7 |
| allergic dna | #7 |
| suspension 01 | #7 |
| prostaglandin atopic | #7 |
| mmc observed | #7 |
| western blotting nfκb | #7 |
| tears th2 | #7 |
| ulcers revealed | #7 |
| 10 clinical signs | #7 |
| eyelid surface | #7 |
| severe persistent cases | #7 |
| hyperemia adverse | #7 |
| conjunctiva brush | #7 |
| improvements symptom scores | #7 |
| sensitization asian | #7 |
| normal blinking | #7 |
| mmc 005 | #7 |
| hrtii rcm | #7 |
| amniotic membrane patching | #7 |
| 0001 impression | #7 |
| cytology differ | #7 |
| accommodating intraocular lens | #7 |
| collected brush | #7 |
| sources chemokines | #7 |
| silicone plugs | #7 |
| allergic eyelid | #7 |
| injection oedema | #7 |
| key prostaglandin | #7 |
| conjunctivitis dry | #7 |
| tmh measurements | #7 |
| eyes ophthalmologists | #7 |
| meniscometry testing | #7 |
| incidence meibomian | #7 |
| examination tear | #7 |
| necrotizing anterior | #7 |
| tacrolimus topical steroids | #7 |
| mucins tears | #7 |
| procedures radioimmunoassay | #7 |
| attendance allergic | #7 |
| thought pathogenesis | #7 |
| steroidal benzophenones | #7 |
| rose bengal fluorescein | #7 |
| concentrations conjunctival | #7 |
| solution bf | #7 |
| papillae formation | #7 |
| neutrophils corneal | #7 |
| conjunctivitis eyes | #8 |
| pollen odds | #8 |
| noninfectious corneal | #8 |
| surface teros | #8 |
| infrared radiation thermometry | #8 |
| akc subjects | #8 |
| sac akc | #8 |
| pathogenesis test | #8 |
| asia cats | #8 |
| induced intraocular | #8 |
| ccl5 conjunctiva | #8 |
| ulcers detected | #8 |
| values slit | #8 |
| conjunctival findings | #8 |
| controls seldi | #8 |
| microscopy conjunctival | #8 |
| age 170 ± | #8 |
| patients vkc | #8 |
| akc patients controls | #8 |
| teros | #8 |
| hoc analysis study | #8 |
| diameter acinar | #8 |
| fluorescein rose bengal | #8 |
| alterations allergic | #8 |
| tnfalpha eosinophils | #8 |
| 006 degree | #8 |
| transient burning sensation | #8 |
| flare counts | #8 |
| trabeculectomy amniotic | #8 |
| il4 enzyme | #8 |
| limbalbased conjunctival flap | #8 |
| underwent tear | #8 |
| mitomycin post | #8 |
| chemotaxis pgd2 | #8 |
| brush cytology | #8 |
| teros values | #8 |
| betamethasone calcineurin | #8 |
| correlation vital | #8 |
| corneal fibroblasts tnfalpha | #8 |
| patients corneal | #8 |
| oedema scores | #8 |
| 4 chemokines | #8 |
| scores teros | #8 |
| itching hyperemia | #8 |
| keratocytes cytokines | #8 |
| conjunctival sensation | #8 |
| rollable intraocular | #8 |
| allergic dibenzazepines | #8 |
| definite dry eye | #8 |
| meniscometry tear | #8 |
| blinking body | #8 |
| corneal epithelial lesions | #8 |
| ihc hel | #8 |
| graticule scale | #8 |
| corneal scores | #8 |
| stained hel | #8 |
| staining hel | #8 |
| occlusion lacrimal | #8 |
| stainings schirmer | #8 |
| palpebral bulbar | #8 |
| controls brush | #8 |
| eye redness | #8 |
| corneal ulcer | #8 |
| superficial cells groups | #8 |
| blinking desiccation | #8 |
| classified allergic | #8 |
| expressions thought | #8 |
| fva measurements | #8 |
| blink patients | #8 |
| par2 mast cells | #8 |
| techniques keratoconjunctivitis | #8 |
| radiation thermography | #8 |
| meniscometry scores | #8 |
| alterations cornea | #8 |
| concentration tears | #9 |
| eye normal subjects | #9 |
| cases conjunctivitis | #9 |
| histocytological study | #9 |
| fatigue dry | #9 |
| operatedon eye | #9 |
| implantation 1cu | #9 |
| pilocarpine tablets | #9 |
| mmc recurrence | #9 |
| pathogen allergic | #9 |
| sensitivity conjunctival | #9 |
| design eyelid | #9 |
| differ allergic | #9 |
| wash solution | #9 |
| 0001 schirmer | #9 |
| excision intraoperative | #9 |
| shield ulcers | #9 |
| level pollutants | #9 |
| superior limbic | #9 |
| vital stainings | #9 |
| tnfalpha fibroblasts | #9 |
| supply superior | #9 |
| subjective ocular | #9 |
| prospective study tacrolimus | #9 |
| conjunctival fibroblast | #9 |
| hel 4 | #9 |
| inflammation steroidal | #9 |
| glaucoma younger age | #9 |
| conjunctivitis cases | #9 |
| crth2 expression eosinophils | #9 |
| prevalence vkc | #9 |
| tacrolimus treating | #9 |
| tear level | #9 |
| injection edema | #9 |
| prevalence weather | #9 |
| vital staining scores | #9 |
| tacrolimus 95 | #9 |
| eye grade | #9 |
| observed obstructive | #9 |
| untreated asian | #9 |
| acid goblet | #9 |
| patients tacrolimus treatment | #9 |
| pretreatment docosahexaenoic | #9 |
| ono2235 | #9 |
| cys eye | #9 |
| sio2 pbs | #9 |
| hyperemia iop | #9 |
| elisa tears | #9 |
| clinical ocular findings | #9 |
| foreign body sensation | #9 |
| severity corneal | #9 |
| genes cxc | #9 |
| cobblestone papillae | #9 |
| fluorescein rose | #9 |
| reductase cataract | #9 |
| pollution conjunctivitis | #9 |
| tears thermography | #9 |
| specular microscopic evaluation | #9 |
| diseases conjunctivitis | #9 |
| sufficient examination | #9 |
| received preserved | #9 |
| diagnosis conjunctivitis | #9 |
| sensitivity confocal | #9 |
| stress staining | #9 |
| smart eye | #9 |
| symptoms allergic conjunctivitis | #9 |
| blood level tacrolimus | #9 |
| measurements vital | #9 |
| icam1 tnfalpha | #10 |
| drugs conjunctival | #10 |
| humans mucin | #10 |
| aged conjunctivitis | #10 |
| cornea eosinophils | #10 |
| par2 mast | #10 |
| eye clinically | #10 |
| laminin actins | #10 |
| measurement strip | #10 |
| ophthalmic adolescent | #10 |
| conjunctivitis japan | #10 |
| crth2 chemotaxis | #10 |
| conjunctival edema | #10 |
| muc16 muc5ac | #10 |
| substance tears | #10 |
| insufficient local | #10 |
| subbasal stromal | #10 |
| nonallergic conjunctivitis | #10 |
| total tear ige | #10 |
| allergic ocular | #10 |
| patients ulcers | #10 |
| staining oral | #10 |
| proliferation conjunctival | #10 |
| tear cytology | #10 |
| iop hyperemia | #10 |
| vmr values | #10 |
| produced conjunctival | #10 |
| humans conjunctival | #10 |
| evaluation atopic | #10 |
| compared eyes | #10 |
| complain | #10 |
| underwent slit | #10 |
| improvement tear | #10 |
| chemokines cxc chemokines | #10 |
| incubated il4 | #10 |
| diagnosis dry eye | #10 |
| lower tmh | #10 |
| functions dry | #10 |
| assessed conjunctival | #10 |
| eye infrared | #10 |
| measuring tear | #10 |
| shield ulcer | #10 |
| conjunctivitis atopic | #10 |
| conjunctivitis spring | #10 |
| staining brush | #10 |
| layer alterations | #10 |
| eye surface | #10 |
| bengal stainings | #10 |
| lacrimal puncta | #10 |
| scale tear | #10 |
| resection regrowth | #10 |
| sensation ocular | #10 |
| punctal occlusion | #10 |
| visante optical | #10 |
| cytometry il4 | #10 |
| levels tears | #10 |
| conjunctivitis histamine | #10 |
| muc5ac muc16 | #10 |
| topical cyclosporine patients | #10 |
| meibomian gland obstruction | #10 |
| allergic conjunctivitis spring | #10 |
| central graft | #10 |
| tears 10 | #10 |
| allergic bronchitis | #10 |
| leupeptin benzamidine | #10 |
| treatment vkc | #10 |
| status conjunctival | #10 |
| therapy conjunctivitis | #11 |
| common conjunctival | #11 |
| vkc adolescent | #11 |
| drop artificial | #11 |
| lamp microscope | #11 |
| diagnosis allergic | #11 |
| disease edition | #11 |
| smart eye camera | #11 |
| landolt visual | #11 |
| prevalence dry eye | #11 |
| vernal | #11 |
| tears conjunctival | #11 |
| test tear | #11 |
| interleukin4 male | #11 |
| elasticity treatment | #11 |
| keratitis observed | #11 |
| patient atopic | #11 |
| elisa il4 | #11 |
| cytometry oligonucleotide | #11 |
| 1 month reduction | #11 |
| hel hne | #11 |
| vcam1 tnfalpha | #11 |
| sensation staining | #11 |
| sensation tear | #11 |
| higher muc1 | #11 |
| elicited statistically | #11 |
| initiation tacrolimus | #11 |
| weeks papillary | #11 |
| amniotic membrane patch | #11 |
| preserved artificial | #11 |
| function ocular | #11 |
| fibroblasts pathogenesis | #11 |
| palpebral bulbar conjunctiva | #11 |
| vmr fva | #11 |
| matched dry | #11 |
| levocabastine hydrochloride | #11 |
| genes corneal | #11 |
| methods conjunctival | #11 |
| count conjunctivitis | #11 |
| ophthalmic solution | #11 |
| anesthesia strabismus | #11 |
| coherence dry | #11 |
| vkc | #11 |
| purpose metaplasia | #11 |
| eosinophils prostaglandin | #11 |
| cooling operation | #11 |
| association outpatient | #11 |
| surgery 13 eyes | #11 |
| antivcaigg | #11 |
| schirmer1 test | #11 |
| vkc normal | #11 |
| expression 8 genes | #12 |
| density muc5ac | #12 |
| density acinar | #12 |
| keratoconjunctivitis patients | #12 |
| 001 specimens | #12 |
| acids chemokine | #12 |
| specimens eyes | #12 |
| dermatitis tacrolimus | #12 |
| conjunctival injection | #12 |
| receptor crth2 | #12 |
| drugs pge2 | #12 |
| lacrimal punctal | #12 |
| severe binocular | #12 |
| 002 ophthalmic | #12 |
| mmhg elevation | #12 |
| biomarker allergic | #12 |
| surface diabetic | #12 |
| damage height | #12 |
| corneal shield | #12 |
| conventional slit | #12 |
| levocabastine patients | #12 |
| extracts pollens | #12 |
| supratarsal injection | #12 |
| highspeed highresolution | #12 |
| coated lactoferrin | #12 |
| eye diagnosed | #12 |
| microscopy efficient | #12 |
| keratoplasty glaucoma | #12 |
| pemirolast potassium | #12 |
| 1cu accommodating | #12 |
| 1821 subjects | #12 |
| ulcers squamous | #12 |
| radiography tears | #12 |
| selected severity | #12 |
| projects tears | #12 |
| appearance atopic | #12 |
| 1cu iol | #12 |
| cornea density | #12 |
| corneal aesthesiometry | #12 |
| immunologic rejection | #12 |
| fluorescein scores | #12 |
| findings conjunctival | #12 |
| ccl11 conjunctiva | #12 |
| mgd controls | #12 |
| fva visual | #12 |
| controls antibody titers | #12 |
| iop glucocorticoids humans | #12 |
| patients sac | #12 |
| tears conjunctivitis | #12 |
| fva vmr | #12 |
| leupeptins mast | #12 |
| iop younger | #12 |
| glaucoma younger | #13 |
| 5ac ophthalmic | #13 |
| inflammation tear | #13 |
| vmr measurements | #13 |
| scraped samples | #13 |
| japan keratoconjunctivitis | #13 |
| stability vital | #13 |
| coherence viscosupplements | #13 |
| tear hel | #13 |
| topical cyclosporine treatment | #13 |
| papillary samples | #13 |
| improvement vital | #13 |
| anterior segment photography | #13 |
| outcomes 01 | #13 |
| chemokines stimulation | #13 |
| suspensions tacrolimus | #13 |
| blood levels tacrolimus | #13 |
| applied operation | #13 |
| specimens levels | #13 |
| corneal complications | #13 |
| aged disposable | #13 |
| compared postsurgical | #13 |
| week corneal | #13 |
| ulcers corneal | #13 |
| syndrome reactivation | #13 |
| upper tarsal | #13 |
| time fluorescein | #13 |
| conjunctival oedema | #13 |
| sd105 | #13 |
| remodeling relevant | #13 |
| interferometry tear | #13 |
| dry eye examination | #13 |
| protein conjunctival | #13 |
| objective signs | #13 |
| called giant | #13 |
| keratocytes incubated | #13 |
| months healed | #13 |
| conclusions ocular | #13 |
| fluorometholone fml | #13 |
| bengal fluorescein | #13 |
| cell flare | #13 |
| symptoms conjunctival | #13 |
| temperature cataract | #13 |
| epithelial disease | #13 |
| thirty eyes | #13 |
| treatment allergic conjunctivitis | #13 |
| glaucoma keratoplasty | #13 |
| tear functions | #13 |
| schirmers test values | #13 |
| epithelial muc5ac | #14 |
| clinically allergic | #14 |
| solutions retrospective | #14 |
| fungi adolescent | #14 |
| visits allergic | #14 |
| 14 flare | #14 |
| pilocarpine effective | #14 |
| factors conjunctivitis | #14 |
| eyes 002 | #14 |
| vehicle eye | #14 |
| radioimmunoassay tears | #14 |
| flare count | #14 |
| mcfg treatment | #14 |
| conjunctival muc5ac | #14 |
| fluorometholone humans | #14 |
| fibroblast damage | #14 |
| density tear | #14 |
| clinical corneal | #14 |
| higher allergic | #14 |
| conjunctival impression | #14 |
| schirmer1 | #14 |
| occlusion dry | #14 |
| functions corneal | #14 |
| blinking patients | #14 |
| dry eye controls | #14 |
| conjunctival allergen challenge | #14 |
| secrete mediators | #14 |
| test rose | #14 |
| benzamidines blotting | #14 |
| conjunctivitis background | #14 |
| bf 01 | #14 |
| conjunctivitis vernal | #14 |
| proliferative lesion | #14 |
| cornea endophthalmitis | #14 |
| adherence fibroblasts | #15 |
| surface vital | #15 |
| expression realtime pcr | #15 |
| ulcer echinocandins | #15 |
| steroidal cornea | #15 |
| superior conjunctiva | #15 |
| patients vernal | #15 |
| day bf | #15 |
| ocular acrylic | #15 |
| investigated corneal | #15 |
| mucous discharge | #15 |
| diseases 2020 | #15 |
| receptor pgd2 | #15 |
| ige ecp | #15 |
| eye drop treatment | #15 |
| occlusion oct | #15 |
| monitoring tear | #15 |
| olopatadine 01 | #15 |
| complications mmc | #15 |
| correlation tear | #15 |
| corneal recurrence | #15 |
| analysis par2 | #15 |
| ocular itching | #15 |
| giant papillary | #15 |
| ocular surface mucins | #15 |
| mmc female follow | #15 |
| rtpcr cytometry | #15 |
| tranilast anti | #15 |
| vkc methods | #15 |
| effects benzalkonium | #15 |
| improvement corneal | #15 |
| evaluation conjunctival | #15 |
| tmh values | #15 |
| basal tear secretion | #15 |
| agents blepharitis | #15 |
| examined existence | #15 |
| topical 01 | #15 |
| damaged fibroblasts | #15 |
| cytology brush | #15 |
| ophthalmology tokyo | #15 |
| blepharitis conjunctivitis | #15 |
| irritation scores | #15 |
| firstline drug | #15 |
| bromobenzenes child | #15 |
| complications height | #15 |
| bilateral conjunctivitis | #15 |
| improvement subjective symptoms | #15 |
| occlusion rose | #15 |
| treatment eyelid | #16 |
| odds ratio remission | #16 |
| measurements tear | #16 |
| ulcers positive | #16 |
| dust allergic | #16 |
| ige correlation | #16 |
| total clinical scores | #16 |
| controls papillary | #16 |
| segment photography | #16 |
| safety 01 | #16 |
| 2 conjunctival | #16 |
| objective ocular | #16 |
| reduction goblet | #16 |
| alpha ortho | #16 |
| female goblet | #16 |
| hours visit | #16 |
| fungi odds | #16 |
| lacrimation | #16 |
| temperature conjunctiva | #16 |
| ari administration | #16 |
| patients vernal keratoconjunctivitis | #16 |
| eosinophils receptor | #16 |
| assessment conjunctival | #16 |
| expression eotaxin1 | #17 |
| fibroblasts damaged | #17 |
| sclera trabeculectomy | #17 |
| meniscometry | #17 |
| ocular allergic inflammation | #17 |
| inhibitor ari | #17 |
| 20 normal patients | #17 |
| conjunctival samples | #17 |
| clearance corneal | #17 |
| analyzed 005 | #17 |
| age dry | #17 |
| muc16 mrna | #17 |
| wear soft | #17 |
| staining muc1 | #17 |
| warmer treatment | #17 |
| agents cedrus | #17 |
| inflammation blotting | #17 |
| betamethasone induced | #17 |
| drops eyes | #17 |
| 13 females age | #17 |
| initiation objective | #17 |
| fibroblasts mcp1 | #17 |
| corneal sensation | #17 |
| increased goblet cells | #17 |
| eyes schirmer | #17 |
| evaluation inflammatory | #17 |
| signs ded | #17 |
| strip meniscometry | #17 |
| ceramide gel | #17 |
| technique glaucoma | #18 |
| obstructive dysfunction | #18 |
| evaluation tear | #18 |
| rantes response | #18 |
| decrease ocular | #18 |
| trabeculectomy glaucoma | #18 |
| cytology decrease | #18 |
| conclusion ocular | #18 |
| dibenzazepines dibenzoxepins | #18 |
| ulceration subjects | #18 |
| 30 ige | #18 |
| ocular surface status | #18 |
| pollen fungi | #18 |
| male ophthalmic solutions | #18 |
| correlation clinical signs | #18 |
| tear function | #18 |
| tnfα inflammatory response | #18 |
| ulcers compared | #18 |
| test tears | #18 |
| studies rose | #18 |
| lower eyes | #18 |
| complete staining | #18 |
| higher tears | #18 |
| induce corneal | #18 |
| noncl wearers | #18 |
| fibroblasts giant | #18 |
| differentiation inflammatory cells | #18 |
| intraoperative 002 | #18 |
| cd45 inflammatory | #18 |
| types dry eye | #18 |
| groups spt | #18 |
| tear evaporation rate | #18 |
| inflammation lenses | #18 |
| bengal sjogren | #18 |
| cytology corneal | #18 |
| associations level | #18 |
| concentrations corneal | #18 |
| prospective study eyes | #19 |
| conjunctivitis topical | #19 |
| temperature artificial | #19 |
| microscopy scans | #19 |
| staining scores | #19 |
| early efficacy | #19 |
| vernal keratoconjunctivitis | #19 |
| operation applied | #19 |
| human conjunctival | #19 |
| seldi proteinchip | #19 |
| seldi analysis | #19 |
| aged cautery | #19 |
| limbal allograft | #19 |
| beta1 il1beta | #19 |
| eosinophils adhered | #19 |
| outpatient attendance | #19 |
| 3 severe | #19 |
| evaluated infrared | #19 |
| steroid female | #19 |
| periostin biomarker | #19 |
| mitomycin ophthalmologic | #19 |
| sma performed | #19 |
| ige tear | #19 |
| inflammatory cells patients | #19 |
| effective tacrolimus | #19 |
| total signs | #19 |
| measurements visante | #19 |
| subjects underwent | #19 |
| aged ophthalmic | #19 |
| sodium 01 | #19 |
| 1151 years | #19 |
| dha pretreatment | #19 |
| corneal impression | #20 |
| cytology upper | #20 |
| ulcers cell | #20 |
| mucin alterations | #20 |
| explain pathogenesis | #20 |
| height tmh | #20 |
| evaluate noninferiority | #20 |
| persistent epithelial defect | #20 |
| summarized based | #20 |
| allergic female humans | #20 |
| pollen association | #20 |
| common ocular disorders | #20 |
| xerophthalmia adolescent | #20 |
| treated 01 | #20 |
| patients strip | #20 |
| symptoms allergic | #20 |
| conjunctivitis primary | #20 |
| lower dry | #20 |
| conclusion tacrolimus | #20 |
| echinocandins eye | #20 |
| tears corneal | #20 |
| surface findings | #20 |
| plaques graded | #20 |
| proteins tears | #20 |
| improvements ocular | #20 |
| decreased conjunctival | #20 |
| conjunctivitis caused | #20 |
| bilateral agerelated cataract | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| 022 pg | #20 |
| symptoms include | #21 |
| methane nonmethane hydrocarbons | #21 |
| fluorescence postoperative | #21 |
| surface mucin | #21 |
| crth2 expressed | #21 |
| conclusions topical | #21 |
| eosinophils flow cytometry | #21 |
| reduction topical | #21 |
| radiation thermometer | #21 |
| eye control | #21 |
| ocular symptoms signs | #21 |
| patients cedar | #21 |
| ige groups | #21 |
| eye smaller | #21 |
| preventing corneal | #21 |
| induced topical | #21 |
| microscopy patients | #21 |
| film lipid | #21 |
| cultured conjunctiva | #21 |
| acuity assessment | #21 |
| conjunctiva role | #21 |
| reaction tears | #21 |
| levels hel | #21 |
| peripheral blood eosinophils | #21 |
| lipid oxidative | #21 |
| tears blood | #21 |
| cornea clinical | #21 |
| keratoconjunctivitis atopic | #21 |
| adhesion fibroblast | #21 |
| patients concomitant treatment | #21 |
| flare anterior | #22 |
| accommodation amplitude | #22 |
| 01 tacrolimus | #22 |
| fibroblasts anti | #22 |
| eyes nerve | #22 |
| mgd adult | #22 |
| serum periostin patients | #22 |
| 005 topical | #22 |
| muc5ac patients | #22 |
| types ocular | #22 |
| therapies allergic | #22 |
| correlation humidity | #22 |
| epithelial lipid | #22 |
| haze photorefractive | #22 |
| negative lower | #22 |
| fluorescein staining | #22 |
| score deqs | #23 |
| patients topical steroids | #23 |
| function mucin | #23 |
| hrt confocal | #23 |
| labeling tears | #23 |
| subjects squamous | #23 |
| pge2 supernatants | #23 |
| 5 females | #23 |
| corneal fluorescein | #23 |
| cooling applied | #23 |
| 215 ± | #23 |
| layer interferometry | #23 |
| prospectively surgery | #23 |
| lamp examinations | #23 |
| preschool conjunctivitis | #23 |
| diseases diclofenac | #23 |
| solution compared | #23 |
| il4 tnf | #23 |
| palpebral conjunctiva | #23 |
| tear dynamics | #23 |
| tests adenovirus | #23 |
| 01 severe | #23 |
| blood concentration tacrolimus | #23 |
| solution corneal | #23 |
| disease atopic | #23 |
| diseases web | #24 |
| cell meter | #24 |
| control tear | #24 |
| samples conjunctival | #24 |
| formation allergic | #24 |
| interleukin4 oligonucleotide | #24 |
| fungal corneal | #24 |
| vital staining | #24 |
| conjunctiva diabetes | #24 |
| local allergic reaction | #24 |
| 27yearold male patient | #24 |
| layer tear | #24 |
| patients tacrolimus ointment | #24 |
| vkc patients | #24 |
| edema drug | #24 |
| surface tear | #24 |
| tarsal conjunctiva | #24 |
| histamine development | #24 |
| warming device | #24 |
| bengal tears | #24 |
| signs serum | #24 |
| dermatitis improved | #24 |
| tokyo dental | #24 |
| ocular allergies | #24 |
| level tears | #25 |
| rsv rtpcr | #25 |
| density squamous | #25 |
| vcam1 activated | #25 |
| eyes epithelial | #25 |
| superficial cells | #25 |
| rtpcr rsv | #25 |
| protein rtpcr | #25 |
| slitlamp examinations | #25 |
| vkc compared | #25 |
| confocal prospective | #25 |
| corneal plaques | #25 |
| patients atopic diseases | #25 |
| dynamics tear | #25 |
| antigen conjunctiva | #25 |
| atopic eosinophils humans | #25 |
| bengal scores | #25 |
| schedule eosinophil | #25 |
| 0001 dry | #25 |
| steroid eye | #25 |
| staining goblet | #25 |
| wheal diameter | #26 |
| dmem f12 medium | #26 |
| correlated corneal | #26 |
| adhered fibroblasts | #26 |
| 100 nylon | #26 |
| postkeratoplasty glaucoma | #26 |
| conjunctival inflammation | #26 |
| damage adhesion | #26 |
| human α defensin | #26 |
| 005 immunoreactive | #26 |
| rapid epithelialization | #26 |
| statistical decrease | #26 |
| keratoconjunctivitis caused | #26 |
| aureus detected | #26 |
| smallincision cataract surgery | #26 |
| solutions corneal | #26 |
| diseases ambient | #26 |
| corneal ulcers | #26 |
| conjunctivitis | #26 |
| slit lamp examinations | #26 |
| specific ige positivity | #26 |
| tbut tear | #26 |
| subjects measuring | #26 |
| symptoms itching | #26 |
| singletreatment groups | #26 |
| eyes topical | #26 |
| acinar unit | #26 |
| actins collagen | #26 |
| 01 topical | #26 |
| lnfs | #26 |
| conclusions improvement | #26 |
| treatment meibomian | #26 |
| level il4 | #26 |
| oct prospective | #27 |
| child cytological | #27 |
| antibodies brush | #27 |
| epinastine | #27 |
| associations prevalence | #27 |
| eosinophils fibroblasts | #27 |
| factor exacerbation | #27 |
| alpha eosinophils | #27 |
| conjunctival epithelial | #27 |
| therapy conjunctiva | #27 |
| cytometry chemotaxis | #27 |
| 005 symptoms | #27 |
| reaction sensation | #27 |
| lymphocytes specimens | #27 |
| interleukin4 polymerase | #27 |
| density subbasal | #27 |
| prescribed topical | #27 |
| tear ocular | #27 |
| 01 cyclosporine | #27 |
| severe ocular | #28 |
| assay eosinophils | #28 |
| corneal vivo | #28 |
| il13 il1beta | #28 |
| diseases proliferative | #28 |
| corneal ulceration | #28 |
| stress atopic | #28 |
| 2 iol | #28 |
| ophthalmic | #28 |
| solutions ophthalmologic | #28 |
| 4 5ac | #28 |
| prevalence allergic diseases | #28 |
| eosinophil adherence | #28 |
| giant papillae | #28 |
| conjunctival epithelial cells | #28 |
| assessment tear | #28 |
| conjunctiva dexamethasone | #28 |
| chemotactic activity eosinophils | #28 |
| provide relief | #28 |
| underwent immunohistochemical | #28 |
| papillae patients | #28 |
| objective scores | #28 |
| rosebengal | #29 |
| ketotifen fumarate | #29 |
| corneal conjunctival | #29 |
| flare cell | #29 |
| 5ac mucins | #29 |
| conjunctiva dose | #29 |
| performed morphometric | #29 |
| thermography adolescent | #29 |
| inhibited tranilast | #29 |
| disease periostin | #29 |
| studies conjunctivitis | #29 |
| numbers inflammatory | #29 |
| allergic regulation | #29 |
| eye mask | #29 |
| aged thermography | #29 |
| cys treatment | #29 |
| scores schirmer | #29 |
| sac compared | #29 |
| symptoms accompanying | #30 |
| ocular surface alterations | #30 |
| tear serum | #30 |
| conjunctiva cells | #30 |
| regrowth observed | #30 |
| expressed crth2 | #30 |
| eye common | #30 |
| effective artificial | #30 |
| common adverse reaction | #30 |
| recruitment day | #30 |
| syndromes equipment | #30 |
| conjunctivitis humans | #30 |
| mucins ophthalmic | #30 |
| specificity tears | #30 |
| minutes visit | #30 |
| conjunctivitis patients | #30 |
| palpebral | #30 |
| atopic diagnostic | #30 |
| fibroblasts protease | #30 |
| tear ige | #30 |
| inhibitors pollen | #30 |
| infection conjunctival | #30 |
| dermatitis efficacy | #30 |
| redness eye | #30 |
| il2r serum | #30 |
| disease summarized | #31 |
| neutrophils severity | #31 |
| inflammation atopic | #31 |
| epithelial mucins | #31 |
| fibroblasts pcr | #31 |
| schirmer scores | #31 |
| worse observed | #31 |
| pathogenesis corneal | #31 |
| expressed eosinophils | #31 |
| vegf cultured | #31 |
| levels july | #31 |
| dermatitis purpose | #31 |
| atopic 10 | #31 |
| acuity fva | #31 |
| hel levels | #31 |
| combinations eosinophils | #31 |
| scores corneal | #31 |
| ige negative | #31 |
| meibomian gland secretion | #31 |
| properties tears | #31 |
| substantial interrater agreement | #32 |
| tgfbeta1 il1beta | #32 |
| reduced steroid | #32 |
| prostaglandin cell | #32 |
| deqs | #32 |
| diagnosed dry | #32 |
| signs improved | #32 |
| western blotting effects | #32 |
| eye sjögren | #32 |
| conjunctival cells | #32 |
| analysis tears | #32 |
| limbus cornea | #32 |
| keratoconjunctivitis | #32 |
| expressibility | #32 |
| schirmer test values | #32 |
| sign scores | #32 |
| tear meniscus height | #32 |
| edema correlated | #33 |
| numbers quantitative | #33 |
| haze score | #33 |
| 4 grades | #33 |
| muc 1 | #33 |
| iop induced | #33 |
| signs evaluated | #33 |
| visante | #33 |
| seasonal young | #33 |
| allergic double | #33 |
| levocabastine | #33 |
| conclusions confocal | #33 |
| film break | #33 |
| immunoglobulin interferometry | #33 |
| ige histamine | #33 |
| count prostaglandin | #33 |
| atopic skin disease | #33 |
| therapy histamine | #34 |
| conjunctiva cytokines | #34 |
| bengal staining | #34 |
| clinical signs patients | #34 |
| treatment mgd | #34 |
| eye 10 | #34 |
| fluorometholone glucocorticoids | #34 |
| alpha fibroblasts | #34 |
| il1beta tgfbeta1 | #34 |
| eyes corneal | #34 |
| 01 effective | #34 |
| intraocular pressure surgery | #34 |
| fibroblasts purpose | #34 |
| 10 objective | #34 |
| proteinchip array | #34 |
| interrater reproducibility | #35 |
| eye 20 | #35 |
| mucins prospective | #35 |
| adult asthenopia | #35 |
| hypertension tacrolimus | #35 |
| virus capsid antigen | #35 |
| 6 months conclusion | #35 |
| objective symptoms | #35 |
| cyclosporine cys | #35 |
| tear stability | #35 |
| measured tear | #36 |
| ocular surface inflammation | #36 |
| vdt users | #36 |
| humans keratoconjunctivitis | #36 |
| diseases eosinophil | #36 |
| schirmer 1 | #36 |
| resection 005 | #36 |
| tear samples | #36 |
| tear clearance | #36 |
| severe allergic | #36 |
| differential dry | #36 |
| anterior scleritis | #36 |
| functional visual acuity | #36 |
| efficacy groups | #36 |
| eyes acrysof | #36 |
| scleritis episcleritis | #37 |
| wellrecognized risk | #37 |
| 002 mmc | #37 |
| schirmer 1 test | #37 |
| oct effective | #37 |
| tenon anesthesia | #37 |
| tacrolimus 12 | #37 |
| tears tumor | #37 |
| recurrence corneal | #37 |
| eyelid skin | #37 |
| conducted compliance | #37 |
| induced iop | #37 |
| laser flarecell meter | #37 |
| delefilcon | #37 |
| contact lens surface | #37 |
| exhibited correlation | #38 |
| gland lipid | #38 |
| pemirolast | #38 |
| cac japanese | #38 |
| 002 mitomycin | #38 |
| device eye | #38 |
| post cataract | #38 |
| aged olopatadine | #38 |
| allergic cromolyn | #38 |
| phacoemulsification implantation | #38 |
| infiltration corneal | #39 |
| accommodating intraocular | #39 |
| atopic dry | #39 |
| 0001 specimens | #39 |
| cyclosporine dry | #39 |
| cells conjunctiva | #39 |
| solutions patient | #39 |
| degree 20 | #39 |
| tears eye | #39 |
| tests diagnostic accuracy | #39 |
| conjunctiva limbus | #39 |
| patients dry eye | #39 |
| 005 oct | #39 |
| response pretreatment | #39 |
| endothelial rejection | #40 |
| decreased inflammation | #40 |
| eye patients | #40 |
| pharmacology clinical efficacy | #40 |
| samples eyes | #40 |
| acid chemokine | #40 |
| subjects specimens | #40 |
| tmh | #40 |
| drops corneal | #40 |
| biomarkers conjunctiva | #40 |
| ulcers control | #40 |
| treated topical | #41 |
| conjunctivitis gpc | #41 |
| treatment dry | #41 |
| homologous visual | #41 |
| eyes superior | #41 |
| vegf il1beta | #41 |
| α pge2 | #41 |
| pollution severe | #41 |
| il1beta vegf | #41 |
| ecp concentrations | #41 |
| stimulate vascular | #41 |
| epitheliopathy | #41 |
| scans underwent | #42 |
| day eye | #42 |
| october july | #42 |
| allergens conjunctivitis | #42 |
| break time | #42 |
| efficient noninvasive | #42 |
| corneal epithelia | #42 |
| rollable | #43 |
| hydrocarbons data | #43 |
| diseases 2017 | #43 |
| conjunctival hyperemia | #43 |
| eyelid edema | #43 |
| surface years | #43 |
| microscopy central | #43 |
| instability decreased | #43 |
| revised 2010 | #43 |
| limbus corneal | #43 |
| keratolimbal | #43 |
| meniscus treatment | #43 |
| cytology revealed | #43 |
| patients rhinoconjunctivitis | #44 |
| agents keratoconjunctivitis | #44 |
| epithelial defect | #44 |
| il1beta il4 | #44 |
| eye 0001 | #44 |
| collagens fibronectin | #44 |
| elasticity patients | #44 |
| activated il4 | #44 |
| tacrolimus treatment | #44 |
| tryptase par2 | #44 |
| oct assessment | #44 |
| abovementioned drugs | #44 |
| tear meniscus | #44 |
| subjective symptom | #44 |
| cautery female | #44 |
| graded 3 | #45 |
| japan particulate | #45 |
| understanding ocular | #45 |
| 24 seconds | #45 |
| fibroblasts eosinophils | #45 |
| users contact | #45 |
| bovine enteric | #45 |
| adult chemotaxis | #45 |
| body sensation | #45 |
| inflammation ocular surface | #45 |
| metaplasia mucin | #45 |
| signs score | #45 |
| metaplasia grade | #45 |
| fibroblasts expression | #45 |
| laser microscopy | #45 |
| topical tacrolimus treatment | #45 |
| recruiting chemokines | #45 |
| correlation inflammation | #45 |
| elevation iop | #45 |
| rose bengal staining | #45 |
| formation corneal | #45 |
| surgery uncorrected | #45 |
| surface inflammation | #45 |
| superficial punctate keratitis | #45 |
| micafungin mcfg | #45 |
| case corneal | #45 |
| fourgrade scale | #45 |
| efficacy 01 | #46 |
| surface disease | #46 |
| 17 japanese patients | #46 |
| seconds controls | #46 |
| staining conjunctival | #46 |
| suspension effective | #46 |
| graticule | #46 |
| posttreatment findings | #46 |
| il13 serum | #46 |
| fluorometholone | #46 |
| efficacy combined therapy | #46 |
| conjunctival | #46 |
| staining inflammatory | #46 |
| tryptases regulation | #46 |
| status ocular | #46 |
| corneal cells | #46 |
| rate ocular | #47 |
| suspension 4 | #47 |
| purpose efficacy | #47 |
| diameter plant | #47 |
| ulcer score | #47 |
| positive muc5ac | #47 |
| blood level | #47 |
| visante oct | #47 |
| allergic female histamine | #47 |
| patients 01 | #47 |
| implantation acrysof | #48 |
| enhanced benefits | #48 |
| eyes month | #48 |
| sac patients | #48 |
| muc5ac mrna | #48 |
| complications corneal | #48 |
| eyelid warming | #48 |
| stromal nerve | #48 |
| brush cytology specimens | #48 |
| stimulation chemokine | #48 |
| dexamethasone anti | #48 |
| cyclosporine ophthalmic | #48 |
| eosinophils epithelium | #49 |
| tacrolimus female | #49 |
| ocular signs | #49 |
| male tears | #49 |
| adult ca125 | #49 |
| visits air | #49 |
| keratocytes fibroblasts | #49 |
| trabeculectomy eyes | #49 |
| expression crth2 | #49 |
| 1cu | #49 |
| fibroblasts incubated | #49 |
| concentrations tears | #49 |
| cxc chemokine genes | #49 |
| objective findings | #49 |
| measuring corneal | #50 |
| inflammation conjunctiva | #50 |
| test ocular | #50 |
| 4 normal controls | #50 |
| decreased tear | #50 |
| total severity score | #50 |
| aged blinking | #50 |
| trabeculectomy mitomycin | #50 |
| disposable soft | #50 |
| ulcers purpose | #50 |
| meniscus height | #50 |
| schirmers test | #50 |
| dyes fluorophotometry | #50 |
| patient eyes | #50 |
| members japan | #51 |
| crth2 expression | #51 |
| periostin patients | #51 |
| effects docosahexaenoic acid | #51 |
| cells brush | #51 |
| diagnosis dry | #51 |
| ocular surface cells | #51 |
| markers atopic | #51 |
| lenses scls | #51 |
| scls | #51 |
| reduction score | #51 |
| inflammation cataract | #51 |
| inflammation decline | #52 |
| biomarker diseases | #52 |
| month initiation | #52 |
| reaction vehicle | #52 |
| atopic groups | #52 |
| eyelid margins | #52 |
| severity objective | #52 |
| stability corneal | #52 |
| examination parameters | #52 |
| eye normal | #52 |
| pcr tgf | #52 |
| tears tomography | #52 |
| stromal nerves | #53 |
| bromfenac | #53 |
| acuity values | #53 |
| differential eosinophil | #53 |
| chloride bak | #54 |
| 005 month | #54 |
| suspension treatment | #54 |
| lacrimal glands | #54 |
| limbic keratoconjunctivitis | #54 |
| scores tear | #54 |
| vegf protein secretion | #54 |
| presence rsv | #54 |
| oxidation adolescent | #54 |
| obstructive mgd | #54 |
| adult conjunctivitis | #55 |
| local cytokine production | #55 |
| atopic enterotoxins | #55 |
| aged pollen | #55 |
| epithelial cells expression | #55 |
| surface clinical | #55 |
| antagonists allergic | #55 |
| combinedtreatment | #55 |
| conjunctiva drug | #55 |
| ocular signs symptoms | #55 |
| topical adolescent | #56 |
| mechanism giant | #56 |
| film ocular | #56 |
| mucin layer | #56 |
| allergies adolescent | #56 |
| plant pollens | #56 |
| mucin2 mucin4 | #56 |
| solution placebo | #56 |
| eosinophil cationic | #56 |
| atopic patients | #56 |
| 3 dry | #56 |
| ded adult | #56 |
| specular microscopic | #56 |
| cornea cyclooxygenase | #56 |
| pain photophobia | #56 |
| dysfunction atopic | #56 |
| accommodating iol | #57 |
| penetrating limbus | #57 |
| chemotactic responses | #57 |
| humans interleukin4 | #57 |
| insensible administration | #57 |
| giant papillary conjunctivitis | #57 |
| inflammation pge2 | #57 |
| papilla formation | #58 |
| drop treatment | #58 |
| seventyeight eyes | #58 |
| maximum blood concentration | #58 |
| objective sign | #58 |
| alpha defensins | #58 |
| staining tear | #58 |
| schiff staining | #58 |
| disease eyes | #59 |
| findings criteria | #59 |
| type allergic | #59 |
| tear instability | #59 |
| intraoperative mitomycin | #59 |
| pm25 prevalence | #59 |
| daily disposable | #60 |
| mmc 2 | #60 |
| release inhibitor | #60 |
| tacrolimus ointment treatment | #60 |
| evaluation items | #60 |
| pcr severe | #60 |
| compared 0001 | #60 |
| syndromes female | #60 |
| signs severe | #60 |
| diabetic corneal | #60 |
| nonsteroidal blotting | #61 |
| correlation patients | #61 |
| punctal | #61 |
| thermography adult | #61 |
| eotaxin1 expression | #62 |
| allergen mediated | #62 |
| specimens histopathologic | #62 |
| prostaglandin patients | #62 |
| amplitude accommodation | #62 |
| expression eyes | #62 |
| combination epithelium | #62 |
| total clinical | #62 |
| eyes 16 | #62 |
| values tended | #62 |
| corneal stem | #63 |
| micafungin treatment | #63 |
| chamber body | #63 |
| conjunctiva patients | #63 |
| oral pilocarpine | #63 |
| sac age | #63 |
| hypersensitivity japan | #63 |
| il4 role | #63 |
| ulcer endophthalmitis | #63 |
| corneal erosion | #63 |
| patient corneal | #63 |
| factor allergic | #64 |
| radioimmunoassay respiratory | #64 |
| dexamethasone production | #64 |
| positive mucin | #64 |
| density inflammatory | #64 |
| cornea dry | #64 |
| il4 culture | #64 |
| evaluation corneal | #64 |
| eye adolescent | #64 |
| viral radioimmunoassay | #65 |
| mucins rna | #65 |
| dust house | #65 |
| tears biomarkers | #65 |
| live rsv | #65 |
| microscope methods | #65 |
| conclusions corneal | #65 |
| layer speed | #66 |
| treatment immunosuppressive agents | #66 |
| diagnosis therapies | #66 |
| surface epithelial | #66 |
| cases atopic | #66 |
| cyclosporine eye | #67 |
| effects 01 | #67 |
| persistent epithelial | #67 |
| female fluorophotometry | #67 |
| 003 treatment | #67 |
| period oral | #67 |
| agents keratoplasty | #67 |
| time vital | #68 |
| housedust | #68 |
| ointment treatment | #68 |
| eye dry | #68 |
| fibroblasts corneal | #69 |
| glaucoma graft | #69 |
| aged tears | #69 |
| patients eosinophils | #69 |
| ophthalmic solutions | #69 |
| fibroblasts examined | #69 |
| counter drugs | #69 |
| occlusion 005 | #69 |
| 1436 patients | #70 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| visit 4 | #70 |
| schirmer test | #70 |
| rhinoconjunctivitis allergic | #70 |
| drops treatment | #71 |
| lenses dry | #71 |
| dust 20 | #71 |
| allergic dermatitis | #71 |
| factors tears | #71 |
| 16 eyes | #72 |
| ige eosinophil | #72 |
| bulbar conjunctiva | #72 |
| glaucoma trabeculectomy | #72 |
| tear production | #72 |
| extraction conjunctiva | #73 |
| fml | #73 |
| epithelial structure | #73 |
| pollution prevalence | #73 |
| pyridines pyrimidinones | #73 |
| antiallergic agent | #73 |
| surface mucins | #73 |
| punctate keratopathy | #73 |
| fluorophotometry humans | #73 |
| liquid conjunctiva | #73 |
| immunosuppressive treatment patients | #73 |
| inflammatory cell numbers | #74 |
| agents intraocular | #74 |
| mcfg | #74 |
| tacrolimus patients | #74 |
| eosinophils expressed | #74 |
| iol acrysof | #74 |
| evaluation dry | #74 |
| 1 month baseline | #75 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| improved infrared | #75 |
| laser flare | #75 |
| completely controlled | #75 |
| pilocarpine prospective | #75 |
| dust epidemiologic | #75 |
| interleukin4 rna | #76 |
| guidelines allergic | #76 |
| ccchemokine | #76 |
| agents interleukin4 | #76 |
| ophthalmological elasticity | #77 |
| studies suspensions | #77 |
| cornea module | #77 |
| slight elongation | #77 |
| lower tear | #77 |
| signs treatment | #77 |
| vegf tgfbeta1 | #77 |
| cytology samples | #77 |
| cytokines stimulate | #77 |
| chemical mediator | #77 |
| capilia | #77 |
| surgery technique | #77 |
| excision recurrence | #77 |
| concentration il2 | #78 |
| signs observed | #78 |
| concomitant tacrolimus | #78 |
| drops 1 | #78 |
| severity ocular | #78 |
| pollen compared | #78 |
| japanese guideline | #78 |
| ocular pain | #79 |
| dry eye | #79 |
| type allergy | #79 |
| il4 ige | #79 |
| allergic environmental | #79 |
| effects corneal | #79 |
| injection reduction | #79 |
| extended wear | #79 |
| inhibitors leupeptin | #79 |
| permeability cornea | #79 |
| glaucoma penetrating | #79 |
| mediated par2 | #80 |
| mgd patients | #80 |
| medications required | #80 |
| assay epithelial | #80 |
| questionnaires tears | #80 |
| decreased dry | #81 |
| antigens histamine | #81 |
| vegf concentration | #81 |
| caused insufficient | #82 |
| acrysof iol | #82 |
| cytology performed | #82 |
| patients conjunctivitis | #82 |
| prostaglandin reverse | #82 |
| atopic dermatitis study | #82 |
| patients staphylococcus aureus | #83 |
| tear lipid | #83 |
| dental college | #83 |
| complications lenses | #83 |
| data tacrolimus | #83 |
| expression corneal | #83 |
| cytokines vegf | #84 |
| schirmer | #84 |
| earlier published data | #84 |
| correlation corneal | #84 |
| epithelium ocular | #84 |
| papillae | #84 |
| human reverse | #85 |
| patients dry | #85 |
| 18 pg | #85 |
| alterations basal | #85 |
| hyperemia induced | #85 |
| treatment odds ratio | #85 |
| temperature patients | #85 |
| 5 grades | #85 |
| scleritis patients | #85 |
| inhibitors tryptases | #85 |
| combined penetrating | #85 |
| sligkv | #86 |
| daily outpatient | #86 |
| pharmacologic intervention | #86 |
| 284 years | #86 |
| inflammation eye | #86 |
| edema scores | #86 |
| patients eyelid | #86 |
| acuity accommodation | #86 |
| discharge evaluated | #86 |
| tacrolimus young | #87 |
| confocal ophthalmic | #87 |
| detection limit assay | #87 |
| tacrolimus reduced | #87 |
| daily weather conditions | #88 |
| regulation muc5ac | #88 |
| tears | #88 |
| sclera surgical | #88 |
| disease conjunctiva | #88 |
| cells keratocytes | #88 |
| post keratoplasty | #88 |
| eyes 30 | #89 |
| assessment dry | #89 |
| findings severe | #89 |
| seasonal perennial | #89 |
| tears visual | #89 |
| tryptase inhibitors | #89 |
| tears adult | #90 |
| glands microscopy | #90 |
| cytocentrifuge preparations | #90 |
| months signs | #90 |
| decrease corneal | #90 |
| temperature cornea | #90 |
| lower corneal | #90 |
| dressings chronic | #90 |
| early ocular | #90 |
| lenses extended | #91 |
| film breakup | #91 |
| exposure japan | #92 |
| techniques trabeculectomy | #92 |
| procedures phacoemulsification | #92 |
| laser cell | #92 |
| eye corneal | #92 |
| stromal corneal | #93 |
| eye cataract surgery | #93 |
| 7 visit | #93 |
| 005 complications | #93 |
| tears administration | #93 |
| solutions tears | #93 |
| drug fibroblasts | #93 |
| preschool conjunctiva | #93 |
| treatment noninfectious | #93 |
| regulation muc1 | #93 |
| conjunctival specimens | #93 |
| patients correlation | #93 |
| case allergic | #94 |
| exposure exhaust | #94 |
| classification pathogenesis | #94 |
| pgd2 crth2 | #94 |
| reaction physical | #94 |
| pollution weather | #94 |
| eye higher | #95 |
| studies tears | #95 |
| eosinophils patients | #95 |
| twentyeight eyes | #95 |
| induced pgd2 | #95 |
| relevant factor | #95 |
| study cyclosporine | #96 |
| staining fluorescein | #96 |
| protein eosinophilia | #96 |
| higher eyes | #96 |
| 128 eyes | #96 |
| score objective | #96 |
| production pge2 | #97 |
| 1month treatment | #97 |
| treatment ecp | #97 |
| 4 alterations | #97 |
| cells hel | #97 |
| eye tear | #98 |
| eyes study | #98 |
| meniscus patients | #98 |
| staining schirmer | #98 |
| eyes positive | #98 |
| vdts | #98 |
| solution improved | #99 |
| pseudophakic patients | #99 |
| management ocular | #99 |
| 005 recurrence | #99 |
| surgery 6 months | #99 |
| japan post | #99 |
| equivalent 4 | #99 |
| cytology evaluation | #99 |
| ointments tacrolimus | #100 |
| allergic atopic | #100 |
| conjunctiva corneal | #100 |
| postoperatively statistically | #100 |
| terminals contact | #100 |
| confocal scanning | #100 |
| ulcer patient | #100 |
| local pattern | #100 |
| cells severity | #100 |
| corneal abnormalities | #100 |
| eyes 10 | #101 |
| pathogenesis atopic | #101 |
| fibroblasts 2 | #101 |
| therapy conjunctival | #102 |
| severe atopic | #102 |
| keratolimbal allograft | #102 |
| effects tranilast | #102 |
| agents conjunctivitis | #102 |
| disease classified | #102 |
| pathogenesis allergic | #102 |
| prevalence dry | #103 |
| mediated protease | #103 |
| washing solution | #103 |
| chemotaxis experiments | #103 |
| subjective comfort | #103 |
| differences ocular | #104 |
| tears young | #104 |
| patients bf | #104 |
| events scores | #104 |
| syndrome epstein | #104 |
| topic premedication | #104 |
| values vital | #104 |
| topical cyclosporine | #104 |
| allergic cytokines | #104 |
| groups dry | #104 |
| role staphylococcal | #105 |
| baseline initiation | #105 |
| inflammation diagnosis | #105 |
| aged amnion | #105 |
| conjunctival impression cytology | #105 |
| wearing contact | #105 |
| child conjunctival | #105 |
| pressure keratoplasty | #106 |
| 14 eyes | #106 |
| microscopy evaluation | #106 |
| conjunctiva cornea | #106 |
| parameters ocular | #106 |
| adhesion fibroblasts | #106 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| eotaxin1 | #107 |
| superficial punctate | #107 |
| lipid layer | #108 |
| conjunctiva | #108 |
| acuity acrylic | #108 |
| scores symptoms | #108 |
| resins aged | #108 |
| induces chemotaxis | #108 |
| film instability | #108 |
| dry mouth symptoms | #108 |
| levels radioimmunoassay | #108 |
| topical tacrolimus | #108 |
| il4 human | #109 |
| asian dust | #109 |
| corneal inflammatory | #109 |
| effects dha | #109 |
| tear evaporation | #109 |
| level tacrolimus | #109 |
| 4 dry | #109 |
| dysfunction mgd | #110 |
| controls inflammatory | #110 |
| increased evaporation | #110 |
| eyes 9 | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| japanese guidelines | #110 |
| lacrimal salivary | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| strabismus surgery | #113 |
| anterior segment inflammation | #113 |
| papillary conjunctivitis | #113 |
| pcr rsv | #113 |
| dibenzoxepins | #113 |
| solutions platelet | #113 |
| grading scores | #114 |
| diagnosed allergic | #114 |
| incision cataract | #114 |
| eye irritation | #114 |
| layer patients | #114 |
| lesions atopic | #114 |
| conjunctival cell | #115 |
| allergic eye | #115 |
| findings severity | #115 |
| goblet cell density | #115 |
| 13 eyes | #115 |
| male mucin | #115 |
| cholinergic treatment | #115 |
| sjögrens syndrome patients | #115 |
| seconds 0001 | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| ophthalmology prevalence | #117 |
| cooling increased | #117 |
| samples stained | #117 |
| viscosupplements aged | #117 |
| patients seasonal | #117 |
| asia dust | #117 |
| metaplasia mucins | #117 |
| molecule1 interleukin4 | #118 |
| sag genes | #118 |
| generation pge2 | #118 |
| effects docosahexaenoic | #118 |
| immunologic receptors prostaglandin | #118 |
| chemotaxis induced | #119 |
| skin elasticity | #119 |
| topical steroids | #119 |
| week 005 | #119 |
| acuity distance | #119 |
| revealed higher | #119 |
| 39 mmhg | #119 |
| iop observed | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| levels histamine | #121 |
| distance corrected | #121 |
| mitomycin ophthalmic | #121 |
| soft lenses | #121 |
| mitomycinc mmc | #121 |
| chronic allergic | #122 |
| artificial tear | #123 |
| titers ebv | #123 |
| adult conjunctiva | #123 |
| male ointments | #123 |
| collagen conjunctiva | #123 |
| area corneal | #124 |
| eosinophils cell | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| month reduced | #126 |
| subjects vivo | #127 |
| patients atopic | #127 |
| 05ng | #127 |
| nerves studied | #127 |
| 9 genes | #128 |
| gamma increase | #128 |
| soft contact lenses | #128 |
| fibroblast viability | #129 |
| combination steroids | #129 |
| 361 ± | #129 |
| acds | #129 |
| elisa levels | #129 |
| functional visual | #130 |
| fva | #130 |
| patients insignificant | #130 |
| antigen hladr | #131 |
| disease cornea | #131 |
| eyes fluorescein | #132 |
| cataract phacoemulsification | #132 |
| 5ac | #132 |
| management allergic | #132 |
| resection severe | #132 |
| eye drop | #132 |
| keratoplasty adult | #133 |
| treated tacrolimus | #133 |
| proteins mucin | #133 |
| skin water | #133 |
| gene transcription levels | #133 |
| 19 normal subjects | #133 |
| acrylic iol | #134 |
| pcr hla | #134 |
| normal conjunctival | #134 |
| density negative | #134 |
| surface examination | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| antiallergic properties | #137 |
| eosinophil adhesion | #137 |
| dry eye patients | #137 |
| ophthalmological dry | #137 |
| severity 10 | #137 |
| ocular surface | #137 |
| iol groups | #138 |
| asian dust storms | #138 |
| eosinophil cationic protein | #138 |
| ratio remission | #139 |
| protein ecp | #139 |
| authors technique | #139 |
| allergic dogs | #139 |
| suppressed pretreatment | #140 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| findings upper | #142 |
| improvements symptom | #142 |
| interleukin1 interleukin13 | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| studies scleritis | #144 |
| 52 mmhg | #144 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| specimens patient | #145 |
| symptoms ocular | #145 |
| recordable | #145 |
| eye syndromes | #145 |
| schiff reaction | #146 |
| virus pathogen | #146 |
| human conjunctiva | #146 |
| eye clinical | #146 |
| underwent evaluation | #146 |
| fibroblasts alpha | #146 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| diagnosis atopic | #147 |
| hne 4 | #147 |
| required type | #147 |
| 263 years | #147 |
| dscg | #147 |
| impression cytology | #147 |
| ulcer drug | #148 |
| 0001 corneal | #148 |
| increased goblet | #148 |
| dynamic visual acuity | #148 |
| japan phenotype | #149 |
| suspension based | #149 |
| quantitative evaluation | #149 |
| intraocular lens iol | #149 |
| fibroblasts production | #149 |
| patients allergic | #149 |
| cationic protein | #149 |
| concentration tacrolimus | #149 |
| inflammatory cells | #150 |
| pyrimidinones treatment | #150 |
| japanese cedar pollen | #150 |
| inflammation reduction | #151 |
| controls performed | #151 |
| postoperative secondary | #152 |
| tacrolimus treated | #152 |
| par2 reverse | #152 |
| eyes 11 | #153 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| induced eotaxin | #153 |
| symptoms objective | #153 |
| 28 surgery | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| chemokine expression | #156 |
| eyelids female | #156 |
| alcon | #156 |
| association pm25 | #156 |
| inflammatory ocular | #157 |
| lipid infiltration | #157 |
| pcr increase | #157 |
| rates untreated | #157 |
| ointments skin | #157 |
| greater inflammation | #157 |
| analysis prostaglandin | #157 |
| values improved | #157 |
| japan included | #158 |
| acuities | #158 |
| trial tacrolimus | #158 |
| surface status | #158 |
| 3 boys | #159 |
| immunological characteristics | #159 |
| weeks adverse | #159 |
| study inflammation | #160 |
| chemokines production | #161 |
| acid schiff | #161 |
| elevation study | #161 |
| 28 female | #161 |
| mucin 5ac | #161 |
| muc16 | #161 |
| thirtysix eyes | #161 |
| 326 years | #162 |
| surgery topical | #162 |
| distance visual acuity | #162 |
| male meibomian | #162 |
| bromobenzenes | #162 |
| twentynine eyes | #163 |
| visit 7 | #163 |
| studied 21 | #163 |
| oxidative stress status | #163 |
| efficacy tacrolimus | #163 |
| prevalence ocular | #163 |
| olopatadine | #163 |
| il1beta il2 | #163 |
| steroid anti | #164 |
| patients topical | #164 |
| soft contact | #164 |
| 30ng | #164 |
| purpose reported | #164 |
| 002 treatment | #164 |
| spt positive | #164 |
| production prostaglandin | #165 |
| biological dressings | #165 |
| cytometry hla | #166 |
| pgd2 induced | #166 |
| fluorescein humans | #166 |
| eosinophils higher | #167 |
| tacrolimus ointment | #167 |
| cytokines allergic | #167 |
| ulcers erosions | #168 |
| males 5 | #168 |
| seldi | #169 |
| steroidal blotting | #169 |
| studies tacrolimus | #169 |
| eotaxin chemokine | #169 |
| treating refractory | #169 |
| local allergic | #169 |
| patients postsurgical | #169 |
| 12 males | #169 |
| expression chemokines | #170 |
| conjunctiva conjunctival | #171 |
| status inflammation | #171 |
| management enzyme | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| status oxidative | #174 |
| pcr flow | #174 |
| standard conventional | #174 |
| subjective symptoms | #174 |
| slit lamp | #174 |
| vivo confocal | #174 |
| distance acuity | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| aldehydes biomarkers | #177 |
| dust extract | #177 |
| subbasal | #177 |
| study longterm outcomes | #177 |
| treatment corneal | #177 |
| endophthalmitis female | #178 |
| reduction intraocular pressure | #178 |
| acrysof | #178 |
| mild 2 | #178 |
| strabismus adolescent | #178 |
| tryptase | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| 4 female | #180 |
| migration eosinophils | #180 |
| japan young adult | #180 |
| compared eye | #180 |
| dyes follow | #180 |
| myopic regression | #180 |
| ceramides child | #180 |
| lipid study | #181 |
| cutometer | #181 |
| normal control patients | #181 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| serum il4 | #183 |
| male radioallergosorbent | #184 |
| mucin4 mucins | #185 |
| human lymphocyte antigen | #185 |
| igg virus | #185 |
| therapy corneal | #186 |
| examined parameters | #186 |
| nerve prospective | #186 |
| par2 mrna | #187 |
| drug fibroblasts humans | #187 |
| suspensions administration | #187 |
| efficacy topical | #187 |
| corneal fibroblasts | #187 |
| atopic eosinophils | #187 |
| eye symptoms | #188 |
| 19 eyes | #188 |
| il13 increased | #188 |
| corneal sensitivity | #188 |
| seconds patients | #189 |
| allergic cross | #189 |
| sensitivity regulation | #189 |
| production stromal | #189 |
| levels 33 | #190 |
| assisted infrared | #191 |
| infiltrating eosinophils | #191 |
| tear break | #191 |
| effects diesel | #191 |
| improvement subjective | #192 |
| allergic rhinoconjunctivitis | #193 |
| therapeutic study | #193 |
| controls vivo | #193 |
| 26 eyes | #194 |
| reactivation epstein | #195 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| treatment topical | #197 |
| eyes 21 | #197 |
| interleukin4 production | #197 |
| 80 allergens | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| combination topical | #198 |
| elisa performed | #198 |
| tears time | #198 |
| 28 eyes | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| preservative free | #201 |
| photorefractive keratectomy | #201 |
| pollen allergic | #201 |
| mcp1 ip10 | #201 |
| perennial allergic | #201 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| rsv infected | #202 |
| receptor homologous | #202 |
| eosinophils neutrophils | #203 |
| differences iop | #204 |
| vcam1 icam1 | #204 |
| pge2 human | #204 |
| ova alum | #204 |
| grade scale | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| eyes cataract | #206 |
| disease dry | #206 |
| minutes 8 | #206 |
| disease acd | #206 |
| time tbut | #206 |
| ecp levels | #207 |
| pressure lens | #207 |
| formation giant | #207 |
| crth2 | #207 |
| glands middle | #207 |
| count cornea | #207 |
| size contact | #208 |
| fluorescein fluorescent | #208 |
| tears aged | #208 |
| mammalian milk | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| month reduction | #210 |
| human allergic | #210 |
| treatment allergic | #210 |
| oct diagnosis | #211 |
| refractory conventional | #211 |
| antiallergic drug | #211 |
| combination tests | #212 |
| iol patients | #212 |
| inflammation injection | #212 |
| tacrolimus combination | #212 |
| chamber anti | #213 |
| treated refractory | #213 |
| conjunctiva eye | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| nuclear cataract | #219 |
| expressions higher | #219 |
| tranilast | #220 |
| august october | #220 |
| conjunctival biopsy | #220 |
| metabolism lysine | #220 |
| findings inflammation | #221 |
| conjunctivitis acute | #221 |
| cells crth2 | #222 |
| combined therapy | #222 |
| samples correlated | #222 |
| twentyfour eyes | #222 |
| level ambient | #222 |
| diseases dry | #222 |
| 26 control subjects | #224 |
| sensitivity measurements | #224 |
| symptoms short | #224 |
| iop corneal | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| corneal clarity | #228 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| itching | #229 |
| followup cases | #229 |
| eye signs | #230 |
| corrected distance | #230 |
| treatment superior | #230 |
| activity eosinophils | #231 |
| 30 eyes | #231 |
| exhaust particles | #231 |
| events initiation | #232 |
| scleral flap | #232 |
| alpha defensin | #232 |
| examined level | #232 |
| cyclosporine treatment | #233 |
| proteinchip | #233 |
| 791 patients | #233 |
| concomitantly administered | #233 |
| anti allergic | #233 |
| dye staining | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| specimens patients | #236 |
| corneal disease | #236 |
| quantitatively evaluate | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| proliferative lesions | #240 |
| tool quantitative | #240 |
| diagnostic abilities | #240 |
| studied subjects | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cromolyn sodium | #242 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| subjects males | #247 |
| eye drops | #247 |
| equivalent 2 | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| response prostaglandin | #251 |
| labeling intercellular | #251 |
| subjective objective | #252 |
| leukocyte child | #252 |
| seasonal allergic | #252 |
| males 13 | #252 |
| syndrome tears | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| improved vision | #255 |
| corneal female | #255 |
| muc | #255 |
| rantes expression | #256 |
| stability positive | #256 |
| dexamethasone inhibition | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| questionnaire objective | #259 |
| tear | #259 |
| role histamine | #260 |
| eosinophil infiltration | #260 |
| eyes control | #260 |
| month treatment | #260 |
| additional medications | #260 |
| expression rsv | #261 |
| human transcription | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| severity adverse | #264 |
| aged mucin | #264 |
| immunohistochemistry increased | #264 |
| 1 month treatment | #264 |
| keratoplasty pkp | #265 |
| steroid induced | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| signs blood | #267 |
| data weekly | #267 |
| studied production | #268 |
| microscopy negative | #268 |
| respiratory syncytial virus | #268 |
| treatment atopic | #268 |
| patients sjögren syndrome | #268 |
| sodium drug | #269 |
| h1 histamine | #270 |
| aged aldehyde | #270 |
| computer terminals | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| aldose reductase inhibitor | #273 |
| improved visual acuity | #273 |
| 13 males | #273 |
| combination eosinophils | #274 |
| studies stevens | #274 |
| epithelium endothelium | #274 |
| concentration quantitative | #274 |
| meibomian gland dysfunction | #275 |
| meibomian gland | #277 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| individuals pcr | #278 |
| tbut | #278 |
| grading score | #278 |
| 13 females | #279 |
| 0001 diagnosis | #279 |
| bloodaqueous barrier | #279 |
| eyes 14 | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| expressed th2 | #282 |
| disease purpose | #282 |
| cautery | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| amniotic membrane | #285 |
| contralateral eye | #285 |
| atopic | #286 |
| seasons adolescent | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| new antifungal | #294 |
| exponential equation | #294 |
| treatment 01 | #294 |
| levels ige | #295 |
| single therapy | #295 |
| serum periostin | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| severity diagnosis | #300 |
| rose bengal | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| moderate 3 | #303 |
| cobblestone | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| operation patient | #305 |
| scores worse | #305 |
| initiation treatment | #305 |
| piperidines treatment | #306 |
| eczema severity | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| interleukin13 interleukin2 | #309 |
| 10 normal subjects | #309 |
| evaluation groups | #309 |
| comfort level | #310 |
| inflammatory cell | #310 |
| compared simple | #310 |
| cytology specimens | #311 |
| 12 eyes | #311 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| regard age | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| aged staining | #315 |
| eye adult | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| cells cornea | #317 |
| interferometry light | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| dermatitis clinical | #320 |
| fluorophotometry | #320 |
| prospective singlearm study | #320 |
| il8 rantes | #321 |
| cells chemotaxis | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| eyes 19 | #325 |
| 15 30 minutes | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| surgery diabetic | #327 |
| chemokine concentrations | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| receptors il2r | #332 |
| dry eye disease | #332 |
| leukocyte coculture | #333 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| values daily | #335 |
| proprietary | #336 |
| corneal epithelial | #337 |
| 27 eyes | #337 |
| male staphylococcal | #337 |
| daily wear | #339 |
| signs clinical | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| corneal infection | #347 |
| measurements treatment | #347 |
| induced elevation | #348 |
| eyes 13 | #348 |
| expression eosinophils | #348 |
| surgery eye | #350 |
| test values | #350 |
| surface diseases | #352 |
| contrast visual | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| temperature infrared | #355 |
| incidence allergic | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| patients allergy | #357 |
| tear film | #357 |
| local cytokine | #358 |
| eyes 8 | #358 |
| months conventional | #359 |
| tacrolimus tumor | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| treatment ocular | #368 |
| function laser | #368 |
| plant pollen | #368 |
| studies sclera | #368 |
| corneae male | #369 |
| postoperative adhesion | #370 |
| eyes 17 | #370 |
| mucin1 mucin2 | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| assessment severe | #375 |
| improvement local | #375 |
| cornea female | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| 10 normal | #377 |
| higher human | #377 |
| levels atopic | #377 |
| phacoemulsification prospective | #377 |
| 4 lower | #377 |
| treatment eyes | #378 |
| count child | #378 |
| tarsal | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| corneal epithelial cells | #386 |
| ocular diseases | #386 |
| limit assay | #388 |
| surface alterations | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| severity incidence | #390 |
| sde | #390 |
| patients proteins | #391 |
| antiallergic | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| applied 5 | #395 |
| 44 eyes | #395 |
| chronic ocular | #395 |
| relative percentages | #396 |
| opacity corneal | #396 |
| techniques interleukin4 | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| pressure elevation | #399 |
| ocular surface disease | #399 |
| declaration helsinki | #400 |
| remission based | #400 |
| modified boyden | #401 |
| eyes severe | #401 |
| rays male | #402 |
| sedating humans | #403 |
| measurements oct | #404 |
| weather air | #404 |
| vogt | #404 |
| cells allergic | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| improved diagnosis | #407 |
| 137 years | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| acids fibroblasts | #412 |
| eyes 15 | #412 |
| specific total | #412 |
| 3 months treatment | #413 |
| allergic reaction | #413 |
| counts 1 | #413 |
| keratocytes | #414 |
| postoperative inflammation | #416 |
| limbal | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| mucin4 | #419 |
| patients comfort | #419 |
| speed resolution | #419 |
| chemokine ccl11 | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| trabeculectomy visual | #430 |
| production 4 | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| regulation eye | #438 |
| 5 women | #438 |
| methods eye | #438 |
| commercial tests | #439 |
| subjects studied | #440 |
| foldable | #440 |
| interleukin4 il4 | #440 |
| vmr | #441 |
| regulation chemokine | #441 |
| landolt | #441 |
| fluorescein dye | #441 |
| anti vcam1 | #442 |
| adult aldehydes | #442 |
| females normal | #442 |
| male mucin1 | #444 |
| 17 males | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| versus vehicle | #453 |
| antagonists sedating | #453 |
| ketotifen | #453 |
| response allergens | #454 |
| normal patients | #454 |
| surface disorder | #454 |
| vivo confocal microscopy | #454 |
| production clearance | #455 |
| ophthalmic nerve | #455 |
| water evaporation | #455 |
| 8 genes | #455 |
| agonists pilocarpine | #456 |
| humans keratoplasty | #456 |
| normal controls patients | #457 |
| outpatient visits | #457 |
| amnion cell | #457 |
| ocular risk | #457 |
| checker | #459 |
| oct study | #460 |
| distance visual | #461 |
| greatest improvements | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| fibroblasts primary | #478 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| newly formed vessels | #480 |
| height measurement | #480 |
| reduce clinical | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| acuity intraocular | #495 |
| ebv reactivation | #495 |
| months eyes | #498 |
| corneal | #498 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| stain positive | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| infections viral | #501 |
| symptoms efficacy | #501 |
| studies status | #502 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| eye position | #505 |
| 2 daily | #505 |
| airborne particulate matter | #506 |
| correlate severity | #506 |
| inflammatory status | #506 |
| penetrating male | #507 |
| aldose reductase | #509 |
| induced ocular | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| observed baseline | #519 |
| male water | #519 |
| inhibition production | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| dinoprostone epithelial | #525 |
| studies trabeculectomy | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| itchy | #531 |
| rhodanine | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| sac | #539 |
| dependent migration | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| cases flow | #542 |
| administration topical | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| production cultured | #546 |
| ebv nuclear antigen | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| il‐4 | #552 |
| cryptomeria | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| disease ded | #555 |
| genechip | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| ocular infections | #560 |
| eyes iop | #560 |
| differentiation inflammatory | #560 |
| laser trabeculoplasty | #562 |
| eyes 24 | #562 |
| positive 30 | #563 |
| count corneal | #569 |
| 16 age | #569 |
| levels il4 | #570 |
| cultured corneal | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| iop eyes | #580 |
| 4 mrna | #580 |
| fibrosis fluorescent | #582 |
| apparatus male | #582 |
| lesions normal | #582 |
| increase vegf | #584 |
| tnfalpha stimulation | #584 |
| department ophthalmology | #584 |
| symptoms scores | #588 |
| induced 4 | #589 |
| female humans allergic | #589 |
| patients csa | #589 |
| corneal epithelium | #589 |
| hladr antigen | #589 |
| intraocular male | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| assay eye | #597 |
| findings evaluated | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| topical adult | #609 |
| inflammation status | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| ocular allergy | #617 |
| grades 0 | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| glaucoma medications | #625 |
| years studied | #625 |
| lamp examination | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| corneal haze | #636 |
| redness | #636 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| total immunoglobulin | #638 |
| contact lenses | #639 |
| eosinophils | #639 |
| based severity | #639 |
| 511 patients | #640 |
| male rhinitis | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| months 01 | #643 |
| symptoms signs | #643 |
| performed modified | #643 |
| observed follow | #644 |
| mellitus double | #645 |
| fibrosis actins | #645 |
| patients healthy volunteers | #650 |
| expression administration | #651 |
| 2 females | #651 |
| viscosupplements | #651 |
| eosinophils flow | #654 |
| analysis existence | #654 |
| diseases methods | #656 |
| comfortable | #657 |
| lacrimal | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| viruses acute | #669 |
| damage scores | #669 |
| 10 age | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| humans lacrimal | #673 |
| 11 males | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| atopic female humans | #694 |
| cells eye | #694 |
| 1 test | #695 |
| early antigen | #697 |
| inhibition expression | #697 |
| objective assessments | #700 |
| levels detection | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 32 eyes | #724 |
| 088 ± | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| followup treatment | #730 |
| 11 male | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| definition classification | #746 |
| unpaired test | #746 |
| blood eosinophils | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| cornea corneal | #751 |
| daily weather | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| follow cases | #759 |
| iol implantation | #759 |
| allergens anti | #762 |
| intraocular lens implantation | #763 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| blinking | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| lenses intraocular | #792 |
| eyes normal | #792 |
| increased epithelial | #793 |
| techniques laminin | #793 |
| tacrolimus | #793 |
| 4 hne | #794 |
| ocular inflammation | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| report efficacy | #801 |
| positive linear | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| mucin | #813 |
| receptors ccr3 | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| aged cell | #820 |
| concentration dose | #820 |
| interleukin4 | #821 |
| cells eosinophils | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| cases follow | #835 |
| surgical outcome | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| symptoms improved | #843 |
| ocular adolescent | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| levels air | #848 |
| 2 weeks treatment | #848 |
| exhaust | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| histamine h1 | #865 |
| thiazolidines | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| 01 compared | #874 |
| patients eyes | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| benzamidine | #880 |
| h1 antagonists | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| respiratory syncytial | #894 |
| 114 years | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| decreased baseline | #905 |
| benzophenones | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| epithelialization | #937 |
| beta1 tumor | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| humans muscarinic | #946 |
| factor production | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| 2 moderate | #957 |
| scanning confocal | #957 |
| singleagent therapy | #959 |
| aldose | #959 |
| 3 eyes | #959 |
| endpoint baseline | #960 |
| sedating | #961 |
| intracellular infection | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| tenon | #994 |
| observed conclusions | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| methods sixteen | #1002 |
| observed vivo | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| blink | #1017 |
| 1 2 weeks | #1017 |
| impression | #1019 |
| normal volunteers | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| disposable | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| syncytial virus | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| lens capsule | #1116 |
| rose | #1116 |
| 30 patients | #1118 |
| keratopathy | #1121 |
| drops | #1121 |
| 92 years | #1122 |
| popularization | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| assay fibroblasts | #1133 |
| cultures human | #1133 |
| treatment objective | #1133 |
| clinical findings | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| visual acuities | #1140 |
| healthy eyes | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| purpose evaluate | #1171 |
| sjögrens syndrome | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| fibronectins fibrosis | #1189 |
| ophthalmological female | #1189 |
| immune mechanisms | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| higher severe | #1316 |
| chemokines chemotaxis | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| child chromatography | #1321 |
| expressed secreted | #1321 |
| 830 | #1322 |
| ccl11 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| goblet cells | #1451 |
| reduced 1 | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| bulbar | #1502 |
| studies suture | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| disease defined | #1713 |
| outcome visual | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| years 19 | #1754 |
| severity treatment | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| epithelial damage | #1835 |
| mediator release | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| shield | #1860 |
| comparative evaluation | #1860 |
| tnfalpha production | #1862 |
| ari | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 5 minutes | #1970 |
| 9 males | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| coherence treatment | #2038 |
| treated eyes | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| versus normal | #2067 |
| ambient air pollution | #2067 |
| allergens animals | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| endopeptidases serine | #2137 |
| docosahexaenoic acid | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| vital | #2246 |
| rater agreement | #2246 |
| pollens | #2247 |
| scores correlated | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| aged nitrogen | #2415 |
| ophthalmology | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| male polymerase | #2573 |
| flare | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| postsurgical | #2629 |
| eosinophilia female | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| tearing | #2698 |
| bf | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| total ige | #2772 |
| matched normal | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| expression adhesion | #3132 |
| rtpcr | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| microscopy | #3992 |
| chemokines | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| grades | #5747 |
| th2 cells | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| alkylating | #18391 |
| stained | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Bericht ausführen | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Bekannt für Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Bekannt für Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Bekannt für Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Bekannt für Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Bekannt für Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Bekannt für Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Bekannt für Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Bekannt für Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Bekannt für Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Bekannt für Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Bekannt für Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Bekannt für Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Bekannt für Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Bekannt für Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Schlüsselpersonen für Allergic Conjunctivitis
Top -Kols der Welt
Wählen Sie einen Suchphrase aus allergic conjunctivitis , allergic conjunctivitis asthma , allergic conjunctivitis mice , allergic conjunctivitis children , allergic conjunctivitis patients
Hiroshi Fujishima:Expertenwirkung
Konzepte für welcheHiroshi Fujishimahat direkten Einfluss:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Hiroshi Fujishima hat Einfluss:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |